@article{MTMT:34338789,
	title = {Colloidal therapeutics in the management of traumatic brain injury: Portray of biomarkers and drug-targets, preclinical and clinical pieces of evidence and future prospects},
	url = {https://m2.mtmt.hu/api/publication/34338789},
	author = {Arya, Shristi and Bahuguna, Deepankar and Bajad, Gopal and Loharkar, Soham and Devangan, Pawan and Khatri, Dharmendra Kumar and Singh, Shashi Bala and Madan, Jitender},
	doi = {10.1016/j.colsurfb.2023.113509},
	journal-iso = {COLLOID SURFACE B},
	journal = {COLLOIDS AND SURFACES B: BIOINTERFACES},
	volume = {230},
	unique-id = {34338789},
	issn = {0927-7765},
	abstract = {Complexity associated with the aberrant physiology of traumatic brain injury (TBI) makes its therapeutic targeting vulnerable. The underlying mechanisms of pathophysiology of TBI are yet to be completely illustrated. Primary injury in TBI is associated with contusions and axonal shearing whereas excitotoxicity, mitochondrial dysfunction, free radicals generation, and neuroinflammation are considered under secondary injury. MicroRNAs, proinflammatory cytokines, and Glial fibrillary acidic protein (GFAP) recently emerged as biomarkers in TBI. In addition, several approved therapeutic entities have been explored to target existing and newly identified drug-targets in TBI. However, drug delivery in TBI is hampered due to disruption of blood-brain barrier (BBB) in secondary TBI, as well as inadequate drug-targeting and retention effect. Colloidal therapeutics appeared helpful in providing enhanced drug availability to the brain owing to definite targeting strategies. Moreover, immense efforts have been put together to achieve increased bioavailability of therapeutics to TBI by devising effective targeting strategies. The potential of colloidal therapeutics to efficiently deliver drugs at the site of injury and down-regulate the mediators of TBI are serving as novel policies in the management of TBI. Therefore, in present manuscript, we have illuminated a myriad of molecular-targets currently identified and recognized in TBI. Moreover, particular emphasis is given to frame armamentarium of repurpose drugs which could be utilized to block molecular targets in TBI in addition to drug delivery barriers. The critical role of colloidal therapeutics such as liposomes, nanoparticles, dendrimers, and exosomes in drug delivery to TBI through invasive and non-invasive routes has also been highlighted.},
	keywords = {PATHOPHYSIOLOGY; Biomarkers; traumatic brain injury; Drug-targets; Colloidal therapeutics},
	year = {2023},
	eissn = {1873-4367},
	orcid-numbers = {Bajad, Gopal/0000-0001-5988-8380; Devangan, Pawan/0000-0002-2858-3653}
}

@article{MTMT:33868396,
	title = {Cerebrospinal Fluid and Blood Biomarkers in Patients with Post-Traumatic Disorders of Consciousness: A Scoping Review},
	url = {https://m2.mtmt.hu/api/publication/33868396},
	author = {Bagnato, Sergio and Boccagni, Cristina},
	doi = {10.3390/brainsci13020364},
	journal-iso = {BRAIN SCI},
	journal = {BRAIN SCIENCES},
	volume = {13},
	unique-id = {33868396},
	abstract = {(1) Background: Cerebrospinal fluid (CSF) and blood biomarkers are emerging tools used to obtain information on secondary brain damage and to improve diagnostic and prognostic accuracy for patients with prolonged post-traumatic disorders of consciousness (DoC). We synthesized available data from studies evaluating CSF and blood biomarkers in these patients. (2) Methods: A scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist to identify and synthesize data from relevant studies. Studies were identified by PubMed and manual searches. Those involving patients with unresponsive wakefulness syndrome or in a minimally conscious state for >28 days, evaluating CSF or blood biomarkers, and conducted on patients with traumatic brain injuries older than 16 years were included in the review. (3) Results: In total, 17 studies were included. Findings on neurofilament light chain, proteins, metabolites, lipids, amyloid-beta, tau, melatonin, thyroid hormones, microtubule-associated protein 2, neuron-specific enolase, and brain-derived neurotrophic factor were included in the qualitative synthesis. (4) Conclusions: The most promising applications for CSF and blood biomarkers are the monitoring of secondary neurodegeneration, support of DoC diagnoses, and refinement of prognoses, although current evidence remains too scarce to recommend such uses of these biomarkers in clinical practice.},
	keywords = {Prognosis; diagnosis; PLASTICITY; traumatic brain injury; neurodegeneration; biomarker; minimally conscious state; neurofilament light chain; VEGETATIVE STATE; Unresponsive wakefulness syndrome},
	year = {2023},
	eissn = {2076-3425},
	orcid-numbers = {Bagnato, Sergio/0000-0002-6289-1887}
}

@article{MTMT:34555465,
	title = {Navigating the Complexities of Traumatic Encephalopathy Syndrome (TES): Current State and Future Challenges},
	url = {https://m2.mtmt.hu/api/publication/34555465},
	author = {Fesharaki-Zadeh, Arman},
	doi = {10.3390/biomedicines11123158},
	journal-iso = {BIOMEDICINES},
	journal = {BIOMEDICINES},
	volume = {11},
	unique-id = {34555465},
	abstract = {Chronic traumatic encephalopathy (CTE) is a unique neurodegenerative disease that is associated with repetitive head impacts (RHI) in both civilian and military settings. In 2014, the research criteria for the clinical manifestation of CTE, traumatic encephalopathy syndrome (TES), were proposed to improve the clinical identification and understanding of the complex neuropathological phenomena underlying CTE. This review provides a comprehensive overview of the current understanding of the neuropathological and clinical features of CTE, proposed biomarkers of traumatic brain injury (TBI) in both research and clinical settings, and a range of treatments based on previous preclinical and clinical research studies. Due to the heterogeneity of TBI, there is no universally agreed-upon serum, CSF, or neuroimaging marker for its diagnosis. However, as our understanding of this complex disease continues to evolve, it is likely that there will be more robust, early diagnostic methods and effective clinical treatments. This is especially important given the increasing evidence of a correlation between TBI and neurodegenerative conditions, such as Alzheimer's disease and CTE. As public awareness of these conditions grows, it is imperative to prioritize both basic and clinical research, as well as the implementation of necessary safe and preventative measures.},
	keywords = {CEREBROSPINAL-FLUID; MOUSE MODEL; BLOOD-BRAIN-BARRIER; Alzheimer's disease (AD); Biochemistry & Molecular Biology; Medicine, Research & Experimental; Chronic traumatic encephalopathy (CTE); Traumatic brain injury (TBI); CLOSED-HEAD INJURY; Breakdown products; ALPHA-II-SPECTRIN; C-TERMINAL HYDROLASE; INTRACRANIAL LESIONS; traumatic encephalopathy syndrome (TES); ACIDIC PROTEIN-LEVELS},
	year = {2023},
	eissn = {2227-9059}
}

@article{MTMT:33858664,
	title = {Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/33858664},
	author = {Harris, Georgia and Rickard, Jonathan James Stanley and Butt, Gibran and Kelleher, Liam and Blanch, Richard James and Cooper, Jonathan and Oppenheimer, Pola Goldberg},
	doi = {10.1109/RBME.2022.3161352},
	journal-iso = {IEEE REV BIOMED ENG},
	journal = {IEEE REVIEWS IN BIOMEDICAL ENGINEERING},
	volume = {16},
	unique-id = {33858664},
	issn = {1937-3333},
	abstract = {The study of ocular manifestations of neurodegenerative disorders, Oculomics, is a growing field of investigation for early diagnostics, enabling structural and chemical biomarkers to be monitored overtime to predict prognosis. Traumatic brain injury (TBI) triggers a cascade of events harmful to the brain, which can lead to neurodegeneration. TBI, termed the "silent epidemic" is becoming a leading cause of death and disability worldwide. There is currently no effective diagnostic tool for TBI, and yet, early-intervention is known to considerably shorten hospital stays, improve outcomes, fasten neurological recovery and lower mortality rates, highlighting the unmet need for techniques capable of rapid and accurate point-of-care diagnostics, implemented in the earliest stages. This review focuses on the latest advances in the main neuropathophysiological responses and the achievements and shortfalls of TBI diagnostic methods. Validated and emerging TBI-indicative biomarkers are outlined and linked to ocular neuro-disorders. Methods detecting structural and chemical ocular responses to TBI are categorised along with prospective chemical and physical sensing techniques. Particular attention is drawn to the potential of Raman spectroscopy as a non-invasive sensing of neurological molecular signatures in the ocular projections of the brain, laying the platform for the first tangible path towards alternative point-of-care diagnostic technologies for TBI},
	keywords = {Biomarkers; Magnetic Resonance Imaging; MONITORING; Brain Injuries; computed tomography; neurology; neuroimaging; Hospitals; biosensors; Biomedical engineering; optic nerve; Ophthalmology; Molecular imaging; Retina; Raman scattering; OPTICAL SENSORS; Medical Devices; Biomedical optical imaging; Point of care; Biophotonics; Traumatic brain injury (TBI)},
	year = {2023},
	eissn = {1941-1189},
	pages = {530-559},
	orcid-numbers = {Harris, Georgia/0000-0001-8826-7057; Kelleher, Liam/0000-0001-6392-8875; Cooper, Jonathan/0000-0002-2358-1050}
}

@article{MTMT:33812917,
	title = {Nanoporous Carbon Immunosensor for Highly Accurate and Sensitive Clinical Detection of Glial Fibrillary Acidic Protein in Traumatic Brain Injury, Stroke, and Spinal Cord Injury},
	url = {https://m2.mtmt.hu/api/publication/33812917},
	author = {Khetani, S. and Salahandish, R. and Tabor, J.B. and Chilvers, M. and Dukelow, S. and Ho, C. and Campbell, C. and Sen, A. and Debert, C.T. and Sanati-Nezhad, A.},
	doi = {10.1021/acsbiomaterials.3c00048},
	journal-iso = {ACS BIOMAT SCI ENG},
	journal = {ACS BIOMATERIALS-SCIENCE & ENGINEERING},
	unique-id = {33812917},
	issn = {2373-9878},
	abstract = {Elevated glial fibrillary acidic protein (GFAP) in the blood serum is one of the promising bodily fluid markers for the diagnosis of central nervous system (CNS) injuries, including traumatic brain injury (TBI), stroke, and spinal cord injury (SCI). However, accurate and point-of-care (POC) quantification of GFAP in clinical blood samples has been challenging and yet to be clinically validated against gold-standard assays and outcome practices. This work engineered and characterized a novel nanoporous carbon screen-printed electrode with significantly increased surface area and conductivity, as well as preserved stability and anti-fouling properties. This nano-decorated electrode was immobilized with the target GFAP antibody to create an ultrasensitive GFAP immunosensor and quantify GFAP levels in spiked samples and the serum of CNS injury patients. The immunosensor presented a dynamic detection range of 100 fg/mL to 10 ng/mL, a limit of detection of 86.6 fg/mL, and a sensitivity of 20.3 Ω mL/pg mm2 for detecting GFAP in the serum. Its clinical utility was demonstrated by the consistent and selective quantification of GFAP comparable to the ultrasensitive single-molecule array technology in 107 serum samples collected from TBI, stroke, and SCI patients. Comparing the diagnostic and prognostic performance of the immunosensor with the existing clinical paradigms confirms the immunosensor’s accuracy as a potential complement to the existing imaging diagnostic modalities and presents a potential for rapid, accurate, cost-effective, and near real-time POC diagnosis and prognosis of CNS injuries. © 2023 American Chemical Society.},
	keywords = {Brain; PROTEINS; BLOOD; CARBON; diagnosis; Electrodes; traumatic brain injury; stroke; stroke; Cost effectiveness; spinal cord injury; spinal cord injury; Patient rehabilitation; Ultrasensitive; Point of care; traumatic brain injuries; Immunosensors; nanoporous carbons; Glial fibrillary acidic proteins; Central nervous system injuries; nanoporous carbon immunosensor; nanoporous carbon immunosensor; serum bodily fluid; serum bodily fluid},
	year = {2023},
	eissn = {2373-9878}
}

@article{MTMT:34560068,
	title = {Research progress on cerebrospinal fluid markers in traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/34560068},
	author = {Liu, J. and Zhang, G.-B.},
	doi = {10.3969/j.issn.1672-6731.2023.10.003},
	journal-iso = {CHIN J CONTEMP NEUROLNEUROSURG},
	journal = {ZHONGGUO XIANDAI SHENJING JIBING ZAZHI / CHINESE JOURNAL OF CONTEMPORARY NEUROLOGY AND NEUROSURGERY},
	volume = {23},
	unique-id = {34560068},
	issn = {1672-6731},
	year = {2023},
	pages = {884-888}
}

@article{MTMT:34182001,
	title = {Blood-Based Biomarkers in Traumatic Brain Injury: A Narrative Review With Implications for the Legal System},
	url = {https://m2.mtmt.hu/api/publication/34182001},
	author = {McBride, William R. and Eltman, Nicholas R. and Swanson, Randel L.},
	doi = {10.7759/cureus.40417},
	journal-iso = {CUREUS},
	journal = {CUREUS},
	volume = {15},
	unique-id = {34182001},
	abstract = {Traumatic brain injury (TBI) is an increasingly recognized diagnosis with significant, and often costly, associated consequences. Yet, despite their increased recognition, TBIs remain underdiagnosed. This issue is especially prominent in the context of mild TBI (mTBI), where there often exists little to no objective evidence of brain injury. In recent years, considerable effort has been made to better define and interpret known objective markers of TBI, as well as identify and explore new ones. An area of particular interest has focused on research related to blood-based biomarkers of TBI. Advancements in our understanding of TBI-related biomarkers can make it possible to characterize the severity of TBI with greater accuracy, improve our understanding of staging within both the injury process and the recovery process, and help us develop quantifiable metrics representative of reversal and recovery from a brain injury following trauma. Proteomic and non-proteomic blood-based biomarkers are being studied extensively and have shown promise for these purposes. Developments in this realm have significant implications not only for clinical care but also for legislation, as well as civil and criminal litigation. Despite their substantial potential, most of these biomarkers are not yet ready for use within the clinical setting, and therefore, are not appropriate for use within the legal or policy-making systems at this time. Given that existing standardization for the accurate and reliable use of TBI biomarkers is currently insufficient for use within either the clinical or legal realms, such data can be vulnerable to misuse and can even result in the abuse of the legal system for unwarranted gain. Courts will need to carefully evaluate the information presented in their role as gatekeepers of the admissibility of scientific evidence within the legal process. Ultimately, the development of biomarkers should lead to improved clinical care following TBI exposure, coherent and informed laws surrounding TBI, and more accurate and just results in litigation surrounding TBI-related sequelae.},
	keywords = {SERUM; ASSOCIATION; Prognosis; diagnosis; biomarker; brain injury; rehabilitation; Forensic Medicine; Mild; psychiatry; concussion; Clinical utility; NEUROFILAMENT LIGHT; Blood-based biomarker; service members; medical-legal; brain injury medicine; physical medicine and rehabilitation (pm & r)},
	year = {2023},
	eissn = {2168-8184}
}

@article{MTMT:34256205,
	title = {Blood-Based Biomarkers for Neuroprognostication in Acute Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/34256205},
	author = {Nguyen, Andrew M. and Saini, Vishal and Hinson, H. E.},
	doi = {10.1055/s-0043-1775764},
	journal-iso = {SEMIN NEUROL},
	journal = {SEMINARS IN NEUROLOGY},
	unique-id = {34256205},
	issn = {0271-8235},
	abstract = {Acute brain injury causes loss of functionality in patients that often is devastating. Predicting the degree of functional loss and overall prognosis requires a multifaceted approach to help patients, and more so their families, make important decisions regarding plans and goals of care. A variety of blood-based markers have been studied as one aspect of this determination. In this review, we discuss CNS-derived and systemic markers that have been studied for neuroprognostication purposes. We discuss the foundation of each protein, the conditions in which it has been studied, and how the literature has used these markers for interpretation. We also discuss challenges to using each marker in each section as well.},
	keywords = {traumatic brain injury; BLOOD-BASED BIOMARKERS; Cardiac arrest; prognostication},
	year = {2023},
	eissn = {1098-9021}
}

@article{MTMT:34248662,
	title = {Post-mortem detection of neuronal and astroglial biochemical markers in serum and urine for diagnostics of traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/34248662},
	author = {Olczak, Mieszko and Poniatowski, Lukasz A. and Siwinska, Agnieszka and Kwiatkowska, Magdalena},
	doi = {10.1007/s00414-023-02990-7},
	journal-iso = {INT J LEGAL MED},
	journal = {INTERNATIONAL JOURNAL OF LEGAL MEDICINE},
	volume = {137},
	unique-id = {34248662},
	issn = {0937-9827},
	abstract = {Currently available epidemiological data shows that traumatic brain injury (TBI) represents one of the leading causes of death that is associated with medico-legal practice, including forensic autopsy, criminological investigation, and neuropathological examination. Attention focused on TBI research is needed to advance its diagnostics in ante- and post-mortem cases with regard to identification and validation of novel biomarkers. Recently, several markers of neuronal, astroglial, and axonal injury have been explored in various biofluids to assess the clinical origin, progression, severity, and prognosis of TBI. Despite clinical usefulness, understanding their diagnostic accuracy could also potentially help translate them either into forensic or medico-legal practice, or both. The aim of this study was to evaluate post-mortem pro-BDNF, NSE, UCHL1, GFAP, S100B, SPTAN1, NFL, MAPT, and MBP levels in serum and urine in TBI cases. The study was performed using cases (n = 40) of fatal head injury and control cases (n = 20) of sudden death. Serum and urine were collected within similar to 24 h after death and compared using ELISA test. In our study, we observed the elevated concentration levels of GFAP and MAPT in both serum and urine, elevated concentration levels of S100B and SPTAN1 in serum, and decreased concentration levels of pro-BDNF in serum compared to the control group. The obtained results anticipate the possible implementation of performed assays as an interesting tool for forensic and medico-legal investigations regarding TBI diagnosis where the head injury was not supposed to be the direct cause of death.},
	keywords = {URINE; SERUM; NEURON; traumatic brain injury; biomarker; astroglia},
	year = {2023},
	eissn = {1437-1596},
	pages = {1441-1452},
	orcid-numbers = {Siwinska, Agnieszka/0000-0003-0400-2719}
}

@article{MTMT:33868395,
	title = {Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context},
	url = {https://m2.mtmt.hu/api/publication/33868395},
	author = {Tomaiuolo, Rossella and Zibetti, Martina and Di Resta, Chiara and Banfi, Giuseppe},
	doi = {10.3390/jcm12072563},
	journal-iso = {J CLIN MED},
	journal = {JOURNAL OF CLINICAL MEDICINE},
	volume = {12},
	unique-id = {33868395},
	abstract = {Traumatic brain injury affects 69 million people every year. One of the main limitations in managing TBI patients is the lack of univocal diagnostic criteria, including the absence of standardized assessment methods and guidelines. Computerized axial tomography is the first-choice examination, despite the limited prevalence of positivity; moreover, its performance is undesirable due to the risk of radiological exposure, prolonged stay in emergency departments, inefficient use of resources, high cost, and complexity. Furthermore, immediacy and accuracy in diagnosis and management of TBIs are critically unmet medical needs. Especially in the context of sports-associated TBI, there is a strong need for prognostic indicators to help diagnose and identify at-risk subjects to avoid their returning to play while the brain is still highly vulnerable. Fluid biomarkers may emerge as new prognostic indicators to develop more accurate prediction models, improving risk stratification and clinical decision making. This review describes the current understanding of the cellular sources, temporal profile, and potential utility of leading and emerging blood-based protein biomarkers of TBI; its focus is on biomarkers that could improve the management of mild TBI cases and can be measured readily and directly in the field, as in the case of sports-related contexts.},
	keywords = {outcome assessment; Traumatic brain injury (TBI); TBI biomarker; sports-related TBI; brain injury markers/biomarkers},
	year = {2023},
	eissn = {2077-0383},
	orcid-numbers = {Tomaiuolo, Rossella/0000-0002-2828-782X; Zibetti, Martina/0009-0004-9287-9071}
}

@article{MTMT:33868145,
	title = {Ubiquitin C-terminal hydrolase L1 after out-of-hospital cardiac arrest},
	url = {https://m2.mtmt.hu/api/publication/33868145},
	author = {Wihersaari, Lauri and Reinikainen, Matti and Tiainen, Marjaana and Bendel, Stepani and Kaukonen, Kirsi-Maija and Vaahersalo, Jukka and Romppanen, Jarkko and Pettila, Ville B. and Skrifvars, Markus},
	doi = {10.1111/aas.14257},
	journal-iso = {ACTA ANAESTH SCAND},
	journal = {ACTA ANAESTHESIOLOGICA SCANDINAVICA},
	unique-id = {33868145},
	issn = {0001-5172},
	abstract = {Background: We studied the prognostic ability of serum ubiquitin C-terminal hydrolase L1 (UCH-L1) after out-of-hospital cardiac arrest (OHCA), compared to that of neuron-specific enolase (NSE).Methods: In this post-hoc analysis of the FINNRESUSCI study, we measured serum concentrations of UCH-L1 in 249 OHCA patients treated in 21 Finnish intensive care units in 2010-2011. We evaluated the ability of UCH-L1 to predict unfavourable outcome at 12 months (defined as cerebral performance category 3-5) by assessing the area under the receiver operating characteristic curve (AUROC), in comparison with NSE.Results: The concentrations of UCH-L1 were higher in patients with unfavourable outcome than for those with favourable outcome: median concentration 10.8 ng/mL (interquartile range, 7.5-18.5 ng/mL) versus 7.8 ng/mL (5.9-11.8 ng/mL) at 24 h (p < .001), and 16.2 ng/mL (12.2-27.7 ng/mL) versus 11.5 ng/mL (9.0-17.2 ng/mL) (p < .001) at 48 h after OHCA. For UCH-L1 as a 12-month outcome predictor, the AUROC was 0.66 (95% confidence interval, 0.60-0.73) at 24 h and 0.66 (0.59-0.74) at 48 h. For NSE, the AUROC was 0.66 (0.59-0.73) at 24 h and 0.72 (0.65-0.80) at 48 h. The prognostic ability of UCH-L1 was not different from that of NSE at 24 h (p = .82) and at 48 h (p = .23).Conclusion: Concentrations of UCH-L1 in serum were higher in patients with unfavourable outcome than in those with favourable outcome. However, the ability of UCH-L1 to predict unfavourable outcome after OHCA was only moderate and not superior to that of NSE.},
	keywords = {Biomarkers; resuscitation; Cardiac arrest; prognostication; ubiquitin C-terminal hydrolase L1; neurological outcome; OHCA},
	year = {2023},
	eissn = {1399-6576}
}

@article{MTMT:32688987,
	title = {Blood GFAP as an emerging biomarker in brain and spinal cord disorders},
	url = {https://m2.mtmt.hu/api/publication/32688987},
	author = {Abdelhak, Ahmed and Foschi, Matteo and Abu-Rumeileh, Samir and Yue, John K. and D'Anna, Lucio and Huss, Andre and Oeckl, Patrick and Ludolph, Albert C. and Kuhle, Jens and Petzold, Axel and Manley, Geoffrey T. and Green, Ari J. and Otto, Markus and Tumani, Hayrettin},
	doi = {10.1038/s41582-021-00616-3},
	journal-iso = {NAT REV NEUROL},
	journal = {NATURE REVIEWS NEUROLOGY},
	volume = {18},
	unique-id = {32688987},
	issn = {1759-4758},
	abstract = {Blood-derived biomarkers for brain and spinal cord diseases are urgently needed. The introduction of highly sensitive immunoassays led to a rapid increase in the number of potential blood-derived biomarkers for diagnosis and monitoring of neurological disorders. In 2018, the FDA authorized a blood test for clinical use in the evaluation of mild traumatic brain injury (TBI). The test measures levels of the astrocytic intermediate filament glial fibrillary acidic protein (GFAP) and neuroaxonal marker ubiquitin carboxy-terminal hydrolase L1. In TBI, blood GFAP levels are correlated with clinical severity and extent of intracranial pathology. Evidence also indicates that blood GFAP levels hold the potential to reflect, and might enable prediction of, worsening of disability in individuals with progressive multiple sclerosis. A growing body of evidence suggests that blood GFAP levels can be used to detect even subtle injury to the CNS. Most importantly, the successful completion of the ongoing validation of point-of-care platforms for blood GFAP might ameliorate the decision algorithms for acute neurological diseases, such as TBI and stroke, with important economic implications. In this Review, we provide a systematic overview of the evidence regarding the utility of blood GFAP as a biomarker in neurological diseases. We propose a model for GFAP concentration dynamics in different conditions and discuss the limitations that hamper the widespread use of GFAP in the clinical setting. In our opinion, the clinical use of blood GFAP measurements has the potential to contribute to accelerated diagnosis and improved prognostication, and represents an important step forward in the era of precision medicine. In this Review, the authors provide an overview of the evidence regarding the use of blood levels of glial fibrillary acidic protein as a biomarker in a range of neurological diseases, including traumatic brain injury, stroke, multiple sclerosis and Alzheimer disease.},
	keywords = {CEREBROSPINAL-FLUID; PLASMA-LEVELS; SUBARACHNOID HEMORRHAGE; FIBRILLARY ACIDIC PROTEIN; SERUM-LEVELS; Intracerebral hemorrhage; DIAGNOSTIC MARKER; postoperative delirium; C-TERMINAL HYDROLASE-L1},
	year = {2022},
	eissn = {1759-4766},
	pages = {158-172},
	orcid-numbers = {Abdelhak, Ahmed/0000-0001-9731-4169; Foschi, Matteo/0000-0002-0321-7155; Oeckl, Patrick/0000-0002-7652-7023}
}

@article{MTMT:34560080,
	title = {Recent trends and innovations in biosensors development for biomarkers towards monitoring traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/34560080},
	author = {Borumand, M.R. and Babaloii, F. and Mirmotahari, S.A. and Maghsoudi, A.S. and Torabi, R. and Mojtahedzadeh, M. and Norouzi, P. and Rad-Malekshahi, M. and Javar, H.A. and Hassani, S.},
	doi = {10.1016/j.biosx.2022.100247},
	journal-iso = {BIOSENS BIOELECTRON: X},
	journal = {BIOSENSORS AND BIOELECTRONICS: X},
	volume = {12},
	unique-id = {34560080},
	issn = {2590-1370},
	year = {2022}
}

@article{MTMT:32964976,
	title = {Analysis of Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 in Postmortem Serum and Cerebrospinal Fluid in Traumatic Cerebral Deaths},
	url = {https://m2.mtmt.hu/api/publication/32964976},
	author = {Dereli, Ayse Kurtulus and Secme, Mucahit and Acar, Kemalettin},
	doi = {10.33808/clinexphealthsci.943779},
	journal-iso = {CLIN EXP HEALTH SCI},
	journal = {CLINICAL AND EXPERIMENTAL HEALTH SCIENCES},
	volume = {12},
	unique-id = {32964976},
	issn = {2459-1459},
	abstract = {Objective: There is a growing body of research aimed at identifying biological markers that could indicate traumatic cerebral deaths such as traumatic brain damage in the postmortem period. In the event of astrocytic and neuronal injury, glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) are released into cerebrospinal fluid and blood. In the postmortem identification of traumatic brain injury, the present research explores the ability of GFAP and UCH-L1.Methods: Cerebrospinal fluid and blood samples were obtained from medicolegal autopsies, 17 cases with severe head trauma, 9 cases with the non-lethal head trauma group and 18 control cases. UCH-L1 and GFAP levels in postmortem cerebrospinal fluid and serum were determined from an enzyme-linked immunosorbent assay (ELISA).Results: GFAP level in cerebrospinal fluid and serum was 2.68 +/- 0.67 ng/ml and 0.79 +/- 0.92 ng/ml in the lethal head trauma group, 2.74 +/- 0.64 ng/ml and 1.05 +/- 0.68 ng/ml the non-lethal head trauma group and 2.49 +/- 0.55 ng/ml and 1.05 +/- 0.89 ng/ml in the control group, respectively. UCH-L1 level in cerebrospinal fluid and serum was 3.02 +/- 0.68 ng/ml and 2.69 +/- 0.77 ng/ml in the lethal head trauma group, 3.34 +/- 0.70 ng/ml and 2.59 +/- 0.65 ng/ml the non-lethal head trauma group and 3.28 +/- 0.33 ng/ml and 2.74 +/- 0.34 ng/ml in the control group, respectively. Elevated cerebrospinal fluid and serum UCH-L1 and GFAP levels were observed in all cases, although absence of statistically significant difference between the trauma and control groups (p>0.05).Conclusion: Further studies are needed to assess whether postmortem serum and CSF GFAP and UCH-L1 concentrations increase regardless of the cause of death.},
	keywords = {glial fibrillary acidic protein; Autopsy; traumatic brain injury; ubiquitin C-terminal hydrolase L1},
	year = {2022},
	pages = {242-248}
}

@article{MTMT:32965355,
	title = {A Literature Review of Traumatic Brain Injury Biomarkers},
	url = {https://m2.mtmt.hu/api/publication/32965355},
	author = {Ghaith, Hazem S. and Nawar, Asmaa Ahmed and Gabra, Mohamed Diaa and Abdelrahman, Mohamed Essam and Nafady, Mohamed H. and Bahbah, Eshak I and Ebada, Mahmoud Ahmed and Ashraf, Ghulam Md and Negida, Ahmed and Barreto, George E.},
	doi = {10.1007/s12035-022-02822-6},
	journal-iso = {MOL NEUROBIOL},
	journal = {MOLECULAR NEUROBIOLOGY},
	volume = {59},
	unique-id = {32965355},
	issn = {0893-7648},
	abstract = {Research into TBI biomarkers has accelerated rapidly in the past decade owing to the heterogeneous nature of TBI pathologies and management, which pose challenges to TBI evaluation, management, and prognosis. TBI biomarker proteins resulting from axonal, neuronal, or glial cell injuries are widely used and have been extensively studied. However, they might not pass the blood-brain barrier with sufficient amounts to be detected in peripheral blood specimens, and further might not be detectable in the cerebrospinal fluid owing to flow limitations triggered by the injury itself. Despite the advances in TBI research, there is an unmet clinical need to develop and identify novel TBI biomarkers that entirely correlate with TBI pathologies on the molecular level, including mild TBI, and further enable physicians to predict patient outcomes and allow researchers to test neuroprotective agents to limit the extents of injury. Although the extracellular vesicles have been identified and studied long ago, they have recently been revisited and repurposed as potential TBI biomarkers that overcome the many limitations of the traditional blood and CSF assays. Animal and human experiments demonstrated the accuracy of several types of exosomes and miRNAs in detecting mild, moderate, and severe TBI. In this paper, we provide a comprehensive review of the traditional TBI biomarkers that are helpful in clinical practice. Also, we highlight the emerging roles of exosomes and miRNA being the promising candidates under investigation of current research.},
	keywords = {Biomarkers; traumatic brain injury; head injury; miRNA; Exosomes},
	year = {2022},
	eissn = {1559-1182},
	pages = {4141-4158},
	orcid-numbers = {Ashraf, Ghulam Md/0000-0002-9820-2078; Negida, Ahmed/0000-0001-5363-6369; Barreto, George E./0000-0002-6644-1971}
}

@article{MTMT:33179112,
	title = {A brief descriptive outline of the rules of mixed martial arts and concussion in mixed martial arts},
	url = {https://m2.mtmt.hu/api/publication/33179112},
	author = {Hamdan, Jessica L. and Rath, Meghan and Sayoc, Jacqueline and Park, Joon-Young},
	doi = {10.12965/jer.2244146.073},
	journal-iso = {J EXERC REHABIL},
	journal = {JOURNAL OF EXERCISE REHABILITATION},
	volume = {18},
	unique-id = {33179112},
	issn = {2288-176X},
	abstract = {Mixed martial arts (MMA), a combat sport consisting of wrestling, boxing, and martial arts, is a popular activity associated with danger and violence. Of concern are the repetitive head impacts, both subconcussive and concussive, sustained by MMA athletes. The rules of MMA encourage head strikes, but there was no formal concussion protocol in the Ultimate Fighting Championship (UFC) until 2021. Because the UFC was established less than 30 years, the long-term consequences of these repetitive concussive head blows are lacking. In this review, we focus on current literature sought to summarize the current knowledge of repetitive head impacts and concussions in MMA. The objectives were to outline (a) the rules of MMA; (b) the postconcussion protocol for UFC athletes; (c) current behavioral and biochemical diagnostic measures; (d) epidemiology and prevalence of concussion in MMA; (e) long term effects of subconcussive repetitive head impacts; (f) biomechanics of head impacts; and (g) considerations and research topics that warrant future research.},
	keywords = {Mild traumatic brain injury; concussion; chronic traumatic encephalopathy; mixed martial arts; Repetitive subconcussive head impacts},
	year = {2022},
	eissn = {2288-1778},
	pages = {142-154},
	orcid-numbers = {Park, Joon-Young/0000-0002-7705-7086}
}

@article{MTMT:33341015,
	title = {Traumatic Brain Injury Biomarkers, Simulations and Kinetics},
	url = {https://m2.mtmt.hu/api/publication/33341015},
	author = {Hicks, Celeste and Dhiman, Akshima and Barrymore, Chauntel and Goswami, Tarun},
	doi = {10.3390/bioengineering9110612},
	journal-iso = {BIOENGINEERING-BASEL},
	journal = {BIOENGINEERING},
	volume = {9},
	unique-id = {33341015},
	abstract = {This paper reviews the predictive capabilities of blood-based biomarkers to quantify traumatic brain injury (TBI). Biomarkers for concussive conditions also known as mild, to moderate and severe TBI identified along with post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE) that occur due to repeated blows to the head during one's lifetime. Since the pathways of these biomarkers into the blood are not fully understood whether there is disruption in the blood-brain barrier (BBB) and the time it takes after injury for the expression of the biomarkers to be able to predict the injury effectively, there is a need to understand the protein biomarker structure and other physical properties. The injury events in terms of brain and mechanics are a result of external force with or without the shrapnel, in the wake of a wave result in local tissue damage. Thus, these mechanisms express specific biomarkers kinetics of which reaches half-life within a few hours after injury to few days. Therefore, there is a need to determine the concentration levels that follow injury. Even though current diagnostics linking biomarkers with TBI severity are not fully developed, there is a need to quantify protein structures and their viability after injury. This research was conducted to fully understand the structures of 12 biomarkers by performing molecular dynamics simulations involving atomic movement and energies of forming hydrogen bonds. Molecular dynamics software, NAMD and VMD were used to determine and compare the approximate thermodynamic stabilities of the biomarkers and their bonding energies. Five biomarkers used clinically were S100B, GFAP, UCHL1, NF-L and tau, the kinetics obtained from literature show that the concentration values abruptly change with time after injury. For a given protein length, associated number of hydrogen bonds and bond energy describe a lower bound region where proteins self-dissolve and do not have long enough half-life to be detected in the fluids. However, above this lower bound, involving higher number of bonds and energy, we hypothesize that biomarkers will be viable to disrupt the BBB and stay longer to be modeled for kinetics for diagnosis and therefore may help in the discoveries of new biomarkers.},
	keywords = {KINETICS; GFAP; S100B; Half-Life; PTSD; TBI; Total Tau; NF-L; BBB; UCH-L1; CTE},
	year = {2022},
	eissn = {2306-5354}
}

@article{MTMT:32946840,
	title = {The effect of clopidogrel and aspirin on the severity of traumatic brain injury in a rat model},
	url = {https://m2.mtmt.hu/api/publication/32946840},
	author = {Kobeissy, Firas and Mallah, Khalil and Zibara, Kazem and Dakroub, Fatima and Dalloul, Zeinab and Nasser, Mohammad and Nasrallah, Leila and Mallah, Zahraa and El-Achkar, Ghewa A. and Ramadan, Naify and Mohamed, Wael and Mondello, Stefania and Darwish, Hala and Hamade, Eva and Habib, Aida},
	doi = {10.1016/j.neuint.2022.105301},
	journal-iso = {NEUROCHEM INT},
	journal = {NEUROCHEMISTRY INTERNATIONAL},
	volume = {154},
	unique-id = {32946840},
	issn = {0197-0186},
	abstract = {Traumatic Brain Injury (TBI) is one of the leading causes of death and disability worldwide. Aspirin (ASA) and clopidogrel (CLOP) are antiplatelet agents that inhibit platelet aggregation. They are implicated in worsening the intracerebral haemorrhage (ICH) risk post-TBI. However, antiplatelet drugs may also exert a neuroprotective effect post-injury. We determined the impact of ASA and CLOP treatment, alone or in combination, on ICH and brain damage in an experimental rat TBI model. We assessed changes in platelet aggregation and measured serum thromboxane by enzyme immune assay. We also explored a panel of brain damage and apoptosis biomarkers by immunoblotting. Rats were treated with ASA and/or CLOP for 48 h prior to TBI and sacrificed 48 h post-injury. In rats treated with antiplatelet agents prior to TBI, platelet aggregation was completely inhibited, and serum thromboxane was significantly decreased, compared to the TBI group without treatment. TBI increases UCHL-1 and GFAP, but decreases hexokinase expression compared to the non-injured controls. All groups treated with antiplatelet drugs prior to TBI had decreased UCH-L1 and GFAP serum levels compared to the TBI untreated group. Furthermore, the ASA and CLOP single treatments increased the hexokinase serum levels. We confirmed that alpha II-spectrin cleavage increased post-TBI, with the highest cleavage detected in CLOP-treated rats. Aspirin and/or CLOP treatment prior to TBI is a double-edged sword that exerts a dual effect post-injury. On one hand, ASA and CLOP single treatments increase the post-TBI ICH risk, with a further detrimental effect from the ASA + CLOP treatment. On the other hand, ASA and/or CLOP treatments are neuroprotective and result in a favourable profile of TBI injury markers. The ICH risk and the neuroprotection benefits from antiplatelet therapy should be weighed against each other to ameliorate the management of TBI patients.},
	keywords = {ASPIRIN; traumatic brain injury; neuroprotection; Clopidogrel; Intracerebral haemorrhage; Controlled cortical impact},
	year = {2022},
	eissn = {1872-9754},
	orcid-numbers = {Kobeissy, Firas/0000-0002-5008-6944; Mallah, Khalil/0000-0001-7622-8106; Dakroub, Fatima/0000-0002-7432-0977; Nasrallah, Leila/0000-0002-7358-4751; Mohamed, Wael/0000-0003-1317-0829; Mondello, Stefania/0000-0002-8587-3614; Habib, Aida/0000-0001-6027-0043}
}

@{MTMT:34560157,
	title = {Comparing radiation and traumatic brain injuries: New insights},
	url = {https://m2.mtmt.hu/api/publication/34560157},
	author = {Kornguth, S. and Neal, Rutledge J.},
	booktitle = {Cellular, Molecular, Physiological, and Behavioral Aspects of Traumatic Brain Injury},
	doi = {10.1016/B978-0-12-823036-7.00039-6},
	unique-id = {34560157},
	year = {2022},
	pages = {243-255}
}

@article{MTMT:32964896,
	title = {Development of an electrochemical impedance spectroscopy based biosensor for detection of ubiquitin C-Terminal hydrolase L1},
	url = {https://m2.mtmt.hu/api/publication/32964896},
	author = {Lee, Jinhee and Kane, Bryant J. and Khanwalker, Mukund and Sode, Koji},
	doi = {10.1016/j.bios.2022.114232},
	journal-iso = {BIOSENS BIOELECTRON},
	journal = {BIOSENSORS & BIOELECTRONICS},
	volume = {208},
	unique-id = {32964896},
	issn = {0956-5663},
	abstract = {Year over year, the incidence of traumatic brain injury (TBI) in the population is dramatically increasing; thus, timely diagnosis is crucial for improving patient outcomes in the clinic. Ubiquitin C-terminal hydrolase L1 (UCHL1), a blood-based biomarker, has been approved by the FDA as a promising quantitative indicator of mild TBI that arises in blood serum shortly after injury. Current gold standard techniques for its quantitation are timeconsuming and require specific laboratory equipment. Hence, development of a hand-held device is an attractive alternative. In this study, we report a novel system for rapid, one-step electrochemical UCH-L1 detection. Electrodes were functionalized with anti-UCH-L1 antibody, which was used as a molecular recognition element for selective sensing of UCH-L1. Electrochemical impedance spectroscopy (EIS) was used as a transduction method to quantify its binding. When the electrode was incubated with different concentrations of UCH-L1, impedance signal increased against a concentration gradient with high logarithmic correlation. Upon singlefrequency analysis, a second calibration curve with greater signal to noise was obtained, which was used to distinguish physiologically relevant concentrations of UCH-L1. Notably, our system could detect UCH-L1 within 5 min, without a washing step nor bound/free separation, and had resolution across concentrations ranging from 1 pM to 1000 pM within an artificial serum sample. These attributes, together with the miniaturization potential afforded by an impedimetric sensing platform, make this platform an attractive candidate for scale-up as a device for rapid, on-site detection of TBI. These findings may aid in the future development of sensing systems for quantitative TBI detection.},
	keywords = {traumatic brain injury; electrochemical impedance spectroscopy; Immunosensor; Point-of-Care Testing; Ubiquitin C-terminal hydrolase L1 (UCH-L1)},
	year = {2022},
	eissn = {1873-4235},
	orcid-numbers = {Sode, Koji/0000-0002-9833-2091}
}

@article{MTMT:32964977,
	title = {Blood Biomarkers in Brain Injury Medicine},
	url = {https://m2.mtmt.hu/api/publication/32964977},
	author = {McBride, William R. and Conlan, Caroline E. and Barylski, Nicole A. and Warneryd, Amelie C. and Swanson, Randel L.},
	doi = {10.1007/s40141-022-00343-w},
	journal-iso = {CURR PHYS MED REHABIL REP},
	journal = {CURRENT PHYSICAL MEDICINE AND REHABILITATION REPORTS},
	volume = {10},
	unique-id = {32964977},
	abstract = {Purpose of Review This review seeks to explore blood-based biomarkers with the potential for clinical implementation. Recent Findings Emerging non-proteomic biomarkers hold promise for more accurate diagnostic and prognostic capabilities, especially in the subacute to chronic phase of TBI recovery. Furthermore, there is a growing understanding of the overlap between TBI-related and dementia-related blood biomarkers. Given the significant heterogeneity inherent in the clinical diagnosis of traumatic brain injury (TBI), there has been an exponential increase in TBI-related biomarker research over the past two decades. While TBI-related biomarker assessments include both cerebrospinal fluid analysis and advanced neuroimaging modalities, blood-based biomarkers hold the most promise to be non-invasive biomarkers widely available to Brain Injury Medicine clinicians in diverse practice settings. In this article, we review the most relevant blood biomarkers for the field of Brain Injury Medicine, including both proteomic and non-proteomic blood biomarkers, biomarkers of cerebral microvascular injury, and biomarkers that overlap between TBI and dementia.},
	keywords = {Prognosis; diagnosis; traumatic brain injury; biomarker; TBI; concussion},
	year = {2022},
	eissn = {2167-4833},
	pages = {114-121}
}

@article{MTMT:33548839,
	title = {Biomarkers in Traumatic Brain Injuries: Narrative Review},
	url = {https://m2.mtmt.hu/api/publication/33548839},
	author = {Pandey, Vishram and Shukla, Dhaval and Nirmal, Shubham and Devi, Bhagavatula Indira and Christopher, Rita},
	doi = {10.1055/s-0042-1759853},
	journal-iso = {INDIAN JOURNAL OF NEUROTRAUMA},
	journal = {INDIAN JOURNAL OF NEUROTRAUMA},
	volume = {2},
	unique-id = {33548839},
	issn = {0973-0508},
	year = {2022}
}

@article{MTMT:32965354,
	title = {Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature},
	url = {https://m2.mtmt.hu/api/publication/32965354},
	author = {Pareja, Jennifer C. Munoz and Li, Xue and Gandham, Nithya and Wang, Kevin K.},
	doi = {10.1016/j.pediatrneurol.2022.03.002},
	journal-iso = {PEDIATR NEUROL},
	journal = {PEDIATRIC NEUROLOGY},
	volume = {130},
	unique-id = {32965354},
	issn = {0887-8994},
	abstract = {Background: Despite decades of research, outcomes in pediatric traumatic brain injury (pTBI) remain highly variable. Brain biofluid-specific biomarkers from pTBI patients may allow us to diagnose and prognosticate earlier and with a greater degree of accuracy than conventional methods. This manuscript reviews the evidence surrounding current brain-specific biomarkers in pTBI and assesses the temporal relationship between the natural history of the traumatic brain injury (TBI) and measured biomarker levels. Methods: A literature search was conducted in the Ovid, PubMed, MEDLINE, and Cochrane databases seeking relevant publications. The study selection and screening process were documented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. Extraction forms included developmental stages of patients, type and biofluid source of biomarkers, brain injury type, and other relevant data. Results: The search strategy identified 443 articles, of which 150 examining the biomarkers of our interest were included. The references retrieved were examined thoroughly and discussed at length with a pediatric neurocritical care intensivist specializing in pTBI and a Ph.D. scientist with a high degree of involvement in TBI biomarker research, authoring a vast amount of literature in this field. Conclusions: TBI biomarkers might serve as valuable tools in the diagnosis and prognosis of pTBI. However, while each biomarker has its advantages, they are not without limitations, and therefore, further research is critical in pTBI biomarkers.(c) 2022 Elsevier Inc. All rights reserved.},
	keywords = {Biomarkers; diagnostics; traumatic brain injury; Pediatrics},
	year = {2022},
	eissn = {1873-5150},
	pages = {60-68}
}

@article{MTMT:33172758,
	title = {Label-free, ultrasensitive and rapid detection of FDA-approved TBI specific UCHL1 biomarker in plasma using MWCNT-PPY nanocomposite as bio-electrical transducer: A step closer to point-of-care diagnosis of TBI},
	url = {https://m2.mtmt.hu/api/publication/33172758},
	author = {Supraja, Patta and Tripathy, Suryasnata and Vanjari, Siva Rama Krishna and Singh, Shiv Govind},
	doi = {10.1016/j.bios.2022.114631},
	journal-iso = {BIOSENS BIOELECTRON},
	journal = {BIOSENSORS & BIOELECTRONICS},
	volume = {216},
	unique-id = {33172758},
	issn = {0956-5663},
	abstract = {Traumatic Brain Injury (TBI), a major cause of mortality and neurological disability affecting people of all ages worldwide, remains a diagnostic and therapeutic challenge to date. Rapid, ultra-sensitive, selective, and wide-range detection of TBI biomarkers in easily accessible body fluids is an unmet clinical need. Considering this, in this work, we report the design and development of a facile, label-free, highly stable and sensitive, chemi-impedance-based sensing platform for rapid and wide range detection of Ubiquitin-carboxy terminal hydrolase L1 (UCHL1: FDA-approved TBI specific plasma biomarker), using carboxylic functionalized MWCNTs embedded polypyrrole (PPY) nanocomposites (PPY/f-MWCNT). The said nanocomposites were synthesized using chemical oxidative polymerization method. Herein, the functionalized MWCNTs are used as conducting fillers so as to increase the polymer's dielectric constant according to the micro-capacitor model, thereby augmenting both DC electrical conductivity and AC dielectric property of the nanocomposite. The proposed immunosensing platform comprises of PPY/f-MWCNT modified interdigitated microelectrode (ID mu Es) array, on which anti-UCHL1-antibodies are immobilized using suitable covalent chemistry. The AC electrical characterization of the nanocomposite modified ID mu Es, with and without the antibodies, was performed through generic capacitance vs. frequency (C-F, 1 KHz-1 MHz) and capacitance vs. applied bias (C-V, 0.1 V-1 V) measurements, using an Agilent B1500A parametric analyzer. The binding event of UCHL1 peptides to anti-UCHL1-antibodies was transduced in terms of normalised changes in parallel capacitance, via the C-F analysis. Further, we have tested the detection efficiency of the said immunoassay against UCHL1 spiked human plasma samples in the concentration range 10 fg/mL-1 mu g/mL. The proposed sensing platform detected UCHL1 in spiked-plasma samples linearly in the range of 10 fg/mL-1 ng/mL with a sensitivity and LoD of 4.22 ((delta C/C-0)/ng.mL(-1))/cm(2) and 0.363 fg/mL, respectively. Further, it showed excellent stability (30 weeks), repeatability, reproducibility, selectivity and interference-resistance. The proposed approach is label-free, and if desired, can be used in conjunction with DC measurements, for biosensing applications.},
	keywords = {TBI; AC analysis; UCHL1-Plasma; Array of interdigitated microelectrodes; MWCNT-COOH embedded PPY; Chemi-impedance},
	year = {2022},
	eissn = {1873-4235}
}

@article{MTMT:34776740,
	title = {The Clinical Use of Serum Biomarkers in Traumatic Brain Injury: A Systematic Review Stratified by Injury Severity},
	url = {https://m2.mtmt.hu/api/publication/34776740},
	author = {Al-Adli, N. and Akbik, O.S. and Rail, B. and Montgomery, E. and Caldwell, C. and Barrie, U. and Vira, S. and Al, Tamimi M. and Bagley, C.A. and Aoun, S.G.},
	doi = {10.1016/j.wneu.2021.08.073},
	journal-iso = {WORLD NEUROSURG},
	journal = {WORLD NEUROSURGERY},
	volume = {155},
	unique-id = {34776740},
	issn = {1878-8750},
	year = {2021},
	eissn = {1878-8769},
	pages = {e418-e438}
}

@article{MTMT:33638752,
	title = {Post-traumatic Headache and Mild Traumatic Brain Injury: Brain Networks and Connectivity},
	url = {https://m2.mtmt.hu/api/publication/33638752},
	author = {Maleki, Nasim and Finkel, Alan and Cai, Guoshuai and Ross, Alexandra and Moore, R. Davis and Feng, Xuesheng and Androulakis, X. Michelle},
	doi = {10.1007/s11916-020-00935-y},
	journal-iso = {CURR PAIN HEADACHE R},
	journal = {CURRENT PAIN AND HEADACHE REPORTS},
	volume = {25},
	unique-id = {33638752},
	issn = {1531-3433},
	abstract = {Purpose of Review Post-traumatic headache (PTH) consequent to mild traumatic brain injury (mTBI) is a complex, multidimensional, chronic neurological disorder. The purpose of this review is to evaluate the current neuroimaging studies on mTBI and PTH with a specific focus on brain networks and connectivity patterns. Recent Findings We present findings on PTH incidence and prevalence, as well as the latest neuroimaging research findings on mTBI and PTH. Additionally, we propose a new strategy in studying PTH following mTBI. The diversity and heterogeneity of pathophysiological mechanisms underlying mild traumatic brain injury pose unique challenges on how we interpret neuroimaging findings in PTH. Evaluating alterations in the intrinsic brain network connectivity patterns using novel imaging and analytical techniques may provide additional insights into PTH disease state and therefore inform effective treatment strategies.},
	keywords = {TENSION-TYPE HEADACHE; MIGRAINE; MIGRAINE; SYMPTOMS; MRI; FMRI; Iraq; functional connectivity; concussion; concussion; Neuron-specific enolase; STATE FUNCTIONAL CONNECTIVITY; mild traumatic brain injury (mTBI); soldiers; blast exposure; Post-traumatic headache (PTH); STRESS-DISORDER},
	year = {2021},
	eissn = {1534-3081},
	orcid-numbers = {Androulakis, X. Michelle/0000-0002-1833-3474}
}

@article{MTMT:32370651,
	title = {Development and Characterization of a Probe Device toward Intracranial Spectroscopy of Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/32370651},
	author = {Mowbray, Max and Banbury, Carl and Rickard, Jonathan J. S. and Davies, David J. and Oppenheimer, Pola Goldberg},
	doi = {10.1021/acsbiomaterials.0c01156},
	journal-iso = {ACS BIOMAT SCI ENG},
	journal = {ACS BIOMATERIALS-SCIENCE & ENGINEERING},
	volume = {7},
	unique-id = {32370651},
	issn = {2373-9878},
	abstract = {Traumatic brain injury is a leading cause of mortality worldwide, often affecting individuals at their most economically active yet no primary disease-modifying interventions exist for their treatment. Real-time direct spectroscopic examination of the brain tissue within the context of traumatic brain injury has the potential to improve the understanding of injury heterogeneity and subtypes, better target management strategies and organ penetrance of pharmacological agents, identify novel targets for intervention, and allow a clearer understanding of fundamental biochemistry evolution. Here, a novel device is designed and engineered, delivering Raman spectroscopy-based measurements from the brain through clinically established cranial access techniques. Device prototyping is undertaken within the constraints imposed by the acquisition and site dimensions (standard intracranial access holes, probe's dimensions), and an artificial skull anatomical model with cortical impact is developed. The device shows a good agreement with the data acquired via a standard commercial Raman, and the spectra measured are comparable in terms of quality and detectable bands to the established traumatic brain injury model. The developed proof-of-concept device demonstrates the feasibility for real-time optical brain spectroscopic interface while removing the noise of extracranial tissue and with further optimization and in vivo validation, such technology will be directly translatable for integration into currently available standards of neurological care.},
	keywords = {Raman device; intracranial spectroscopy; SKiNET; traumatic brain injury biochemistry},
	year = {2021},
	eissn = {2373-9878},
	pages = {1252-1262},
	orcid-numbers = {Mowbray, Max/0000-0003-1398-0469}
}

@article{MTMT:32420328,
	title = {Sirtuins, a potential target in Traumatic Brain Injury and relevant experimental models},
	url = {https://m2.mtmt.hu/api/publication/32420328},
	author = {Ranadive, Niraja and Arora, Devinder and Nampoothiri, Madhavan and Mudgal, Jayesh},
	doi = {10.1016/j.brainresbull.2021.03.016},
	journal-iso = {BRAIN RES BULL},
	journal = {BRAIN RESEARCH BULLETIN},
	volume = {171},
	unique-id = {32420328},
	issn = {0361-9230},
	abstract = {Traumatic brain injury (TBI) can simply be defined as a violent external injury to the head causing brain dysfunction. The primary injury occurs immediately on impact whereas the secondary injury begins minutes to months after impact. TBI affects a vast majority of population worldwide yet, there isn?t any therapeutic intervention available. Sirtuins (SIRTs) are important regulator proteins found in humans. In several neurodegenerative diseases, SIRTs have proven its neuroprotective actions. Owing to the pathophysiological similarities in these diseases and TBI, SIRTs may serve as a potential target for therapeutic intervention in TBI. This review aims to describe the relevance of SIRTs as a potential pharmacological target in TBI. Also, the experimental animal model of TBI explored to understand the role of SIRTs in TBI have been discussed.},
	keywords = {traumatic brain injury; neuroinflammation; SIRTUINS; glial cell activation},
	year = {2021},
	eissn = {1873-2747},
	pages = {135-141},
	orcid-numbers = {Ranadive, Niraja/0000-0003-3858-1579; Mudgal, Jayesh/0000-0001-8190-7031}
}

@article{MTMT:32188327,
	title = {Molecular and Diffusion Tensor Imaging Biomarkers of Traumatic Brain Injury: Principles for Investigation and Integration},
	url = {https://m2.mtmt.hu/api/publication/32188327},
	author = {Turner, Stephanie and Lazarus, Rachel and Marion, Donald and Main, Keith L.},
	doi = {10.1089/neu.2020.7259},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {38},
	unique-id = {32188327},
	issn = {0897-7151},
	abstract = {The last 20 years have seen the advent of new technologies that enhance the diagnosis and prognosis of traumatic brain injury (TBI). There is recognition that TBI affects the brain beyond initial injury, in some cases inciting a progressive neuropathology that leads to chronic impairments. Medical researchers are now searching for biomarkers to detect and monitor this condition. Perhaps the most promising developments are in the biomolecular and neuroimaging domains. Molecular assays can identify proteins indicative of neuronal injury and/or degeneration. Diffusion imaging now allows sensitive evaluations of the brain's cellular microstructure. As the pace of discovery accelerates, it is important to survey the research landscape and identify promising avenues of investigation. In this review, we discuss the potential of molecular and diffusion tensor imaging (DTI) biomarkers in TBI research. Integration of these technologies could advance models of disease prognosis, ultimately improving care. To date, however, few studies have explored relationships between molecular and DTI variables in patients with TBI. Here, we provide a short primer on each technology, review the latest research, and discuss how these biomarkers may be incorporated in future studies.},
	keywords = {Biomarkers; diffusion tensor imaging; concussion; Clinical Neurology; Critical Care Medicine; Molecular assays},
	year = {2021},
	eissn = {1557-9042},
	pages = {1762-1782}
}

@article{MTMT:32197390,
	title = {Thorough overview of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein as tandem biomarkers recently cleared by US Food and Drug Administration for the evaluation of intracranial injuries among patients with traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/32197390},
	author = {Wang, Kevin K. W. and Kobeissy, Firas H. and Shakkour, Zaynab and Tyndall, J. Adrian},
	doi = {10.1002/ams2.622},
	journal-iso = {ACUTE MEDICINE & SURGERY},
	journal = {ACUTE MEDICINE & SURGERY},
	volume = {8},
	unique-id = {32197390},
	issn = {2052-8817},
	abstract = {Traumatic brain injury (TBI) is a major cause of mortality and morbidity affecting all ages. It remains to be a diagnostic and therapeutic challenge, in which, to date, there is no Food and Drug Administration-approved drug for treating patients suffering from TBI. The heterogeneity of the disease and the associated complex pathophysiology make it difficult to assess the level of the trauma and to predict the clinical outcome. Current injury severity assessment relies primarily on the Glasgow Coma Scale score or through neuroimaging, including magnetic resonance imaging and computed tomography scans. Nevertheless, such approaches have certain limitations when it comes to accuracy and cost efficiency, as well as exposing patients to unnecessary radiation. Consequently, extensive research work has been carried out to improve the diagnostic accuracy of TBI, especially in mild injuries, because they are often difficult to diagnose. The need for accurate and objective diagnostic measures led to the discovery of biomarkers significantly associated with TBI. Among the most well-characterized biomarkers are ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. The current review presents an overview regarding the structure and function of these distinctive protein biomarkers, along with their clinical significance that led to their approval by the US Food and Drug Administration to evaluate mild TBI in patients.},
	keywords = {GFAP; biomarker; brain injury; DIAGNOSTIC MARKER},
	year = {2021},
	orcid-numbers = {Shakkour, Zaynab/0000-0002-5436-1798}
}

@article{MTMT:32689315,
	title = {Role of Salivary Biomarkers in Predicting Significant Traumatic Brain Injury An Exploratory Study},
	url = {https://m2.mtmt.hu/api/publication/32689315},
	author = {Yeung, Claudia and Bhatia, Rahul and Bhattarai, Bikash and Sinha, Madhumita},
	doi = {10.1097/PEC.0000000000002050},
	journal-iso = {PEDIATR EMERG CARE},
	journal = {PEDIATRIC EMERGENCY CARE},
	volume = {37},
	unique-id = {32689315},
	issn = {0749-5161},
	abstract = {Objectives The highest rates of traumatic brain injury (TBI)-related morbidity and mortality occur in young children and adolescents. The objective of this study was to describe the levels of 3 biomarkers (S100B, glial fibrillary acidic protein, neuron-specific enolase) in saliva of children with TBI requiring inpatient admission at a pediatric trauma center and compare these levels in children without TBI. Methods A convenience sample of 24 children aged 0 to 18 years, presenting with acute isolated TBI, was enrolled prospectively. The non-TBI comparison groups consisted of patients with medical complaints and musculoskeletal injuries only. Salivary specimens were collected, and biomarkers were measured using quantitative enzyme-linked immunosorbent assay method. Demographic, clinical data, and brain imaging findings were obtained. Results Seventy-four children were enrolled. Twenty-four had TBI (mean age, 5.07 years; SD, 4.8 years); 14 subjects (58.3%) with TBI were found to have significant traumatic brain injury (SBI) on computed tomography scan. S100B levels were significantly higher in TBI group compared with those with musculoskeletal injury only (median, 113.2 pg/mL vs 18 pg/mL; P = 0.021). Area under the receiver operating characteristic curve for S100B in predicting SBI was 0.675; the optimum threshold for S100B to achieve the optimum sensitivity and specificity of SBI was at 86.9 pg/mL for SBI versus no injury group. Conclusions S100B levels in saliva were higher in children with TBI and may be predictive of SBI identified by presence of computed tomography abnormalities. Larger studies are needed to replicate our findings in using a noninvasive diagnostic measure for children with TBI and SBI.},
	keywords = {SERUM; CEREBROSPINAL-FLUID; glial fibrillary acidic protein; emergency medicine; traumatic brain injury; S100B; FIBRILLARY ACIDIC PROTEIN; Neuron-specific enolase; salivary biomarkers},
	year = {2021},
	eissn = {1535-1815},
	pages = {E1373-E1376}
}

@article{MTMT:31715237,
	title = {Damaged: Elevated GFAP and UCH-L1 as the Black Flag of Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/31715237},
	author = {Anderson, Taylor N. and Hinson, Holly E.},
	doi = {10.1016/j.resuscitation.2020.07.002},
	journal-iso = {RESUSCITATION},
	journal = {RESUSCITATION},
	volume = {154},
	unique-id = {31715237},
	issn = {0300-9572},
	year = {2020},
	eissn = {1873-1570},
	pages = {110-111}
}

@article{MTMT:31446031,
	title = {Management of Traumatic Brain Injury: From Present to Future},
	url = {https://m2.mtmt.hu/api/publication/31446031},
	author = {Crupi, Rosalia and Cordaro, Marika and Cuzzocrea, Salvatore and Impellizzeri, Daniela},
	doi = {10.3390/antiox9040297},
	journal-iso = {ANTIOXIDANTS-BASEL},
	journal = {ANTIOXIDANTS},
	volume = {9},
	unique-id = {31446031},
	abstract = {TBI (traumatic brain injury) is a major cause of death among youth in industrialized societies. Brain damage following traumatic injury is a result of direct and indirect mechanisms; indirect or secondary injury involves the initiation of an acute inflammatory response, including the breakdown of the blood-brain barrier (BBB), brain edema, infiltration of peripheral blood cells, and activation of resident immunocompetent cells, as well as the release of numerous immune mediators such as interleukins and chemotactic factors. TBI can cause changes in molecular signaling and cellular functions and structures, in addition to tissue damage, such as hemorrhage, diffuse axonal damages, and contusions. TBI typically disturbs brain functions such as executive actions, cognitive grade, attention, memory data processing, and language abilities. Animal models have been developed to reproduce the different features of human TBI, better understand its pathophysiology, and discover potential new treatments. For many years, the first approach to manage TBI has been treatment of the injured tissue with interventions designed to reduce the complex secondary-injury cascade. Several studies in the literature have stressed the importance of more closely examining injuries, including endothelial, microglia, astroglia, oligodendroglia, and precursor cells. Significant effort has been invested in developing neuroprotective agents. The aim of this work is to review TBI pathophysiology and existing and potential new therapeutic strategies in the management of inflammatory events and behavioral deficits associated with TBI.},
	keywords = {traumatic brain injury; neuroinflammation; THERAPEUTIC STRATEGIES; Palmitoylethanolamide (PEA); Oxidative stress},
	year = {2020},
	eissn = {2076-3921},
	orcid-numbers = {Crupi, Rosalia/0000-0002-7629-3132; Cordaro, Marika/0000-0002-3980-0043; Cuzzocrea, Salvatore/0000-0001-6131-3690}
}

@article{MTMT:31328719,
	title = {Blood biomarkers on admission in acute traumatic brain injury : Relations to severity, CT findings and care path in the CENTER-TBI study},
	url = {https://m2.mtmt.hu/api/publication/31328719},
	author = {Czeiter, Endre and Amrein, Krisztina and Gravesteijn, Benjamin Y and Lecky, Fiona and Menon, David K and Mondello, Stefania and Newcombe, Virginia F J and Richter, Sophie and Steyerberg, Ewout W and Vyvere, Thijs Vande and Verheyden, Jan and Xu, Haiyan and Yang, Zhihui and Maas, Andrew I R and Wang, Kevin K W and Büki, András},
	doi = {10.1016/j.ebiom.2020.102785},
	journal-iso = {EBIOMEDICINE},
	journal = {EBIOMEDICINE},
	volume = {56},
	unique-id = {31328719},
	issn = {2352-3964},
	abstract = {Serum biomarkers may inform and improve care in traumatic brain injury (TBI). We aimed to correlate serum biomarkers with clinical severity, care path and imaging abnormalities in TBI, and explore their incremental value over clinical characteristics in predicting computed tomographic (CT) abnormalities.We analyzed six serum biomarkers (S100B, NSE, GFAP, UCH-L1, NFL and t-tau) obtained <24 h post-injury from 2867 patients with any severity of TBI in the Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI) Core Study, a prospective, multicenter, cohort study. Univariable and multivariable logistic regression analyses were performed. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC) with 95% confidence intervals.All biomarkers scaled with clinical severity and care path (ER only, ward admission, or ICU), and with presence of CT abnormalities. GFAP achieved the highest discrimination for predicting CT abnormalities (AUC 0•89 [95%CI: 0•87-0•90]), with a 99% likelihood of better discriminating CT-positive patients than clinical characteristics used in contemporary decision rules. In patients with mild TBI, GFAP also showed incremental diagnostic value: discrimination increased from 0•84 [95%CI: 0•83-0•86] to 0•89 [95%CI: 0•87-0•90] when GFAP was included. Results were consistent across strata, and injury severity. Combinations of biomarkers did not improve discrimination compared to GFAP alone.Currently available biomarkers reflect injury severity, and serum GFAP, measured within 24 h after injury, outperforms clinical characteristics in predicting CT abnormalities. Our results support the further development of serum GFAP assays towards implementation in clinical practice, for which robust clinical assay platforms are required.CENTER-TBI study was supported by the European Union 7th Framework program (EC grant 602150).},
	keywords = {SERUM; Biomarkers; GFAP; diagnostic; traumatic brain injury; Computerized tomography; injury severity; clinical decision rule},
	year = {2020},
	eissn = {2352-3964},
	orcid-numbers = {Czeiter, Endre/0000-0002-9578-6944}
}

@article{MTMT:31459443,
	title = {Association of neuronal repair biomarkers with delirium among survivors of critical illness},
	url = {https://m2.mtmt.hu/api/publication/31459443},
	author = {Hayhurst, Christina J. and Patel, Mayur B. and McNeil, J. Brennan and Girard, Timothy D. and Brummel, Nathan E. and Thompson, Jennifer L. and Chandrasekhar, Rameela and Ware, Lorraine B. and Pandharipande, Pratik P. and Ely, E. Wesley and Hughes, Christopher G.},
	doi = {10.1016/j.jcrc.2019.12.010},
	journal-iso = {J CRIT CARE},
	journal = {JOURNAL OF CRITICAL CARE},
	volume = {56},
	unique-id = {31459443},
	issn = {0883-9441},
	abstract = {Purpose: Delirium is prevalent but with unclear pathogenesis. Neuronal injury repair pathways may be protective. We hypothesized that higher concentrations of neuronal repair biomarkers would be associated with decreased delirium in critically ill patients.Materials and methods: We performed a nested study of hospital survivors within a prospective cohort that enrolled patients within 72 h of respiratory failure or shock. We measured plasma concentrations of ubiquitin carboxyl-terminal-esterase-L1 (UCHLI ) and brain-derived neurotrophic factor (BDNF) from blood collected at enrollment. Delirium was assessed twice daily using the CAM-ICU. Multivariable regression was used to examine the associations between biomarkers and delirium prevalence/duration, adjusting for covariates and interactions with age and IL-6 plasma concentration.Results: We included 427 patients with a median age of 59 years (IQR 48-69) and APACHE II score of 25 (IQR 19-30). Higher plasma concentration of UCHLI on admission was independently associated with lower prevalence of delirium (p = .04) but not associated with duration of delirium (p = .06). BDNF plasma concentration was not associated with prevalence (p = .26) or duration of delirium (p = .36).Conclusions: During critical illness, higher UCHLI plasma concentration is associated with lower prevalence of delirium; BDNF plasma concentration is not associated with delirium. (C) 2019 Elsevier Inc. All rights reserved.},
	keywords = {critical illness; COGNITIVE DYSFUNCTION; Brain-derived neumtrophic factor},
	year = {2020},
	eissn = {1557-8615},
	pages = {94-99}
}

@article{MTMT:31459442,
	title = {Plasma Biomarker for Post-concussive Syndrome: A Pilot Study Using an Alternating Current Electro-Kinetic Platform},
	url = {https://m2.mtmt.hu/api/publication/31459442},
	author = {Lewis, Jean M. and Dhawan, Sanjay and Obirieze, Augustine C. and Sarno, Benjamin and Akers, Johnny and Heller, Michael J. and Chen, Clark C.},
	doi = {10.3389/fneur.2020.00685},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {11},
	unique-id = {31459442},
	issn = {1664-2295},
	abstract = {Background:Technology platforms that afford biomarker discovery in patients suffering from traumatic brain injury (TBI) remain an unmet medical need. Here, we describe an observational pilot study to explore the utility of an alternating current electrokinetic (ACE) microchip device in this context. Methods:Blood samples were collected from participating subjects with and without minor TBI. Plasma levels of glial fibrillary acidic protein (GFAP), Tau, ubiquitin C-terminal hydrolase L1 (UCH-L1), and cell-free DNA (cfDNA) were determined in subjects with and without minor TBI using ACE microchip device followed by on-chip immunofluorescent analysis. Post-concussive symptoms were assessed using the Rivermead Post Concussion Symptoms Questionnaire (RPCSQ) at one-month follow-up. Results:Highest levels of GFAP, UCH-L1, and Tau were seen in two minor TBI subjects with abnormality on head computed tomography (CT). In patients without abnormal head CT, Tau and GFAP levels discriminated between plasma from minor-TBI and non-TBI patients, with sensitivity and specificity of 64-72 and 50%, respectively. Plasma GFAP, UCH-L1, and Tau strongly correlated with the cumulative RPCSQ score. Plasma UCH-L1 and GFAP exhibited highest correlation to sensitivity to noise and light (r= 0.96 and 0.91, respectively,p< 0.001). Plasma UCH-L1 and Tau showed highest correlation with headache (r= 0.74 and 0.78, respectively,p< 0.001), sleep disturbance (r= 0.69 and 0.84, respectively,p< 0.001), and cognitive symptoms, including forgetfulness (r= 0.76 and 0.74, respectively,p< 0.001), poor concentration (r= 0.68 and 0.76, respectively,p< 0.001), and time required for information processing (r= 0.77 and 0.81, respectively,p< 0.001). cfDNA exhibited a strong correlation with depression (r= 0.79,p< 0.01) and dizziness (r= 0.69,p< 0.01). While cfDNA demonstrated positive correlation with dizziness and depression (r= 0.69 and 0.79, respectively,p< 0.001), no significant correlation was observed between cumulative RPCSQ and cfDNA (r= 0.07,p= 0.81). Conclusion:We provide proof-of-principle results supporting the utility of ACE microchip for plasma biomarker analysis in patients with minor TBI.},
	keywords = {Biomarkers; traumatic brain injury; Extracellular vesicles; concussion; alternating current electrokinetics},
	year = {2020},
	eissn = {1664-2295}
}

@article{MTMT:31459441,
	title = {Absence of Glia Maturation Factor Protects from Axonal Injury and Motor Behavioral Impairments after Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/31459441},
	author = {Selvakumar, Govindhasamy Pushpavathi and Ahmed, Mohammad Ejaz and Iyer, Shankar S. and Thangavel, Ramasamy and Kempuraj, Duraisamy and Raikwar, Sudhanshu P. and Bazley, Kieran and Wu, Kristopher and Khan, Asher and Kukulka, Klaudia and Bussinger, Bret and Zaheer, Smita and Burton, Casey and James, Donald and Zaheer, Asgar},
	doi = {10.5607/en20017},
	journal-iso = {EXP NEUROBIOL (KOREA)},
	journal = {EXPERIMENTAL NEUROBIOLOGY},
	volume = {29},
	unique-id = {31459441},
	issn = {1226-2560},
	abstract = {Traumatic brain injury (TBI) causes disability and death, accelerating the progression towards Alzheimer's disease and Parkinson's disease (PD). TBI causes serious motor and cognitive impairments. as seen in PD that arise during the period of the initial insult However, this has been understudied relative to TBI induced neuroinflammation, motor and cognitive decline that progress towards PD. Neuronal ubiquitin-C-terminal hydrolase-L1 (UCHL1) is a thiol protease that breaks down ubiquitinated proteins and its level represents the severity of TBI. Previously, vie demonstrated the molecular action of glia maturation factor (GMF); a proinflammatory protein in mediating neuroinflanunation and neuronal loss. Here. we show that the weight drop method induced TBI neuropathology using behavioral tests, western blotting, and immunofluorescence techniques on sections from wild type (WT) and GMF-deficient (GMF-KO) mice. Results reveal a significant improvement in substantia nigral tyrosine hydroxyiase and dopamine transporter expression with motor behavioral performance in GMF-KO mice following TBI. In addition, a significant reduction in neuroinflanunation was manifested, as shown by activation of nuclear factor-kB, reduced levels of inducible nitric oxide synthase, and cyclooxygenase-2 expressions. Likewise, neurotrophins including brain-derived neurotrophic factor and glial-derived neurotrophic factor were significantly improved in GMF-KO mice than WT 72 h post-TBI. Consistently we found that TBI enhances GFAP and UCHL-1 expression and reduces the number of dopaminergic TH-positive neurons in WT compared to GMF-KO mice 72 h post-TBI. Interestingly, we observed a reduction of TH-positive tanycytes in the median eminence of WT than GMF-KO mice. Overall, we found that absence of GMF significantly reversed these neuropathological events and improved behavioral outcome. This study provides evidence that PD-associated pathology progression can be initiated upon induction of TBI.},
	keywords = {traumatic brain injury; Parkinson's disease; neuroinflammation; Motor behavior; glia maturation factor},
	year = {2020},
	eissn = {2093-8144},
	pages = {230-248}
}

@article{MTMT:31308173,
	title = {Biomarkers in traumatic brain injury: new concepts},
	url = {https://m2.mtmt.hu/api/publication/31308173},
	author = {Slavoaca, Dana and Muresanu, Dafin and Birle, Codruta and Rosu, Olivia Verisezan and Chirila, Ioana and Dobra, Iulia and Jemna, Nicoleta and Strilciuc, Stefan and Vos, Pieter},
	doi = {10.1007/s10072-019-04238-y},
	journal-iso = {NEUROL SCI},
	journal = {NEUROLOGICAL SCIENCES},
	volume = {41},
	unique-id = {31308173},
	issn = {1590-1874},
	year = {2020},
	eissn = {1590-3478},
	pages = {2033-2044}
}

@article{MTMT:31714993,
	title = {BDNF and IL-8, But Not UCHL-1 and IL-11, Are Markers of Brain Injury in Children Caused by Mild Head Trauma},
	url = {https://m2.mtmt.hu/api/publication/31714993},
	author = {Tylicka, Marzena and Matuszczak, Ewa and Hermanowicz, Adam and Debek, Wojciech and Karpinska, Maria and Kaminska, Joanna and Koper-Lenkiewicz, Olga Martyna},
	doi = {10.3390/brainsci10100665},
	journal-iso = {BRAIN SCI},
	journal = {BRAIN SCIENCES},
	volume = {10},
	unique-id = {31714993},
	abstract = {The aim of the study was to check whether the plasma levels of brain-derived neurotrophic factor (BDNF), interleukin-8 (IL-8), interleukin-11 (IL-11) and ubiquitin C-terminal hydrolase L1 (UCHL-1) change in children with mild head trauma (N = 29) compared to controls (N = 13). Protein concentration in children with mild head trauma (12 children with mild concussion without loss of consciousness and 17 children with severe concussion and loss of consciousness) and the control group were measured by means of the Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-8 and BDNF concentration was statistically higher in the group of children with mild head trauma (9.89 pg/mL and 2798.00 pg/mL, respectively) compared to the control group (7.52 pg/mL and 1163.20 pg/mL, respectively). BDNF concentration was significantly higher in children with severe concussion and loss of consciousness (3826.00 pg/mL) than in the control group. None of the tested proteins differed significantly between children with mild concussion without loss of consciousness and children with severe concussion and loss of consciousness. BDNF and IL-8 may be sensitive markers of brain response to mild head trauma in children. The lack of statistical differences for BDNF and IL-8 between children with mild or severe concussion could indicate that their elevated levels may not result from significant structural brain damage but rather reflect a functional disturbance.},
	keywords = {brain-derived neurotrophic factor (BDNF); Interleukin-8 (IL-8); mild head trauma; interleukin-11 (IL-11); ubiquitin C-terminal hydrolase L1 (UCHL-1)},
	year = {2020},
	eissn = {2076-3425},
	orcid-numbers = {Hermanowicz, Adam/0000-0002-5723-6941; Karpinska, Maria/0000-0002-5002-2799; Kaminska, Joanna/0000-0002-2986-4852}
}

@article{MTMT:30487576,
	title = {Protein biomarkers of epileptogenicity after traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/30487576},
	author = {Agoston, Denes V. and Kamnaksh, Alaa},
	doi = {10.1016/j.nbd.2018.07.017},
	journal-iso = {NEUROBIOL DIS},
	journal = {NEUROBIOLOGY OF DISEASE},
	volume = {123},
	unique-id = {30487576},
	issn = {0969-9961},
	abstract = {Traumatic brain injury (TBI) is a major risk factor for acquired epilepsy. Post-traumatic epilepsy (PTE) develops over time in up to 50% of patients with severe TBI. PTE is mostly unresponsive to traditional anti-seizure treatments suggesting distinct, injury-induced pathomechanisms in the development of this condition. Moderate and severe TBIs cause significant tissue damage, bleeding, neuron and glia death, as well as axonal, vascular, and metabolic abnormalities. These changes trigger a complex biological response aimed at curtailing the physical damage and restoring homeostasis and functionality. Although a positive correlation exists between the type and severity of TBI and PTE, there is only an incomplete understanding of the time-dependent sequelae of TBI pathobiologies and their role in epileptogenesis. Determining the temporal profile of protein biomarkers in the blood (serum or plasma) and cerebrospinal fluid (CSF) can help to identify pathobiologies underlying the development of PTE, high-risk individuals, and disease modifying therapies. Here we review the pathobiological sequelae of TBI in the context of blood- and CSF-based protein biomarkers, their potential role in epileptogenesis, and discuss future directions aimed at improving the diagnosis and treatment of PTE.},
	keywords = {SERUM; EPILEPSY; cerebrospinal fluid; traumatic brain injury; epileptogenesis; Secondary injury; Protein biomarkers; Post-traumatic epilepsy; Primary injury},
	year = {2019},
	eissn = {1095-953X},
	pages = {59-68}
}

@article{MTMT:30726465,
	title = {The role of UCH-L1, MMP-9, and GFAP as peripheral markers of different susceptibility to seizure development in a preclinical model of epilepsy},
	url = {https://m2.mtmt.hu/api/publication/30726465},
	author = {Chmielewska, Natalia and Maciejak, Piotr and Turzynska, Danuta and Sobolewska, Alicja and Wislowska-Stanek, Aleksandra and Kolosowska, Karolina and Plaznik, Adam and Szyndler, Janusz},
	doi = {10.1016/j.jneuroim.2019.03.018},
	journal-iso = {J NEUROIMMUNOL},
	journal = {JOURNAL OF NEUROIMMUNOLOGY},
	volume = {332},
	unique-id = {30726465},
	issn = {0165-5728},
	abstract = {In our study, we assessed the potency of the brain-derived proteins ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), matrix metalloproteinase 9 (MMP-9), glial fibrillary acidic protein (GFAP) and the immune activation indicators interleukin 1 beta (IL-1 beta) and interleukin 6 (IL-6) as peripheral biomarkers of different susceptibilities to kindling in a preclinical model. We observed increased plasma UCH-L1 levels in kindled vs. control animals. Furthermore, MMP-9 and IL-1 beta concentrations were the lowest in rats resistant to kindling. In summary, UCH-L1 is an indicator of neuronal loss and BBB disruption after seizure. MMP-9 and IL-1 beta may indicate resistance to kindling. UCH-L1, MMP-9 and IL-1 beta may have utility as peripheral biomarkers with translational potency in the clinic.},
	year = {2019},
	eissn = {1872-8421},
	pages = {57-63}
}

@article{MTMT:31568696,
	title = {Single-step functionalization of poly-catecholamine nanofilms for ultra-sensitive immunosensing of ubiquitin carboxyl terminal hydrolase-L1 (UCHL-1) in spinal cord injury},
	url = {https://m2.mtmt.hu/api/publication/31568696},
	author = {Khetani, Sultan and Kollath, Vinayaraj Ozhukil and Eastick, Erin and Debert, Chantel and Sen, Arindom and Karan, Kunal and Sanati-Nezhad, Amir},
	doi = {10.1016/j.bios.2019.111715},
	journal-iso = {BIOSENS BIOELECTRON},
	journal = {BIOSENSORS & BIOELECTRONICS},
	volume = {145},
	unique-id = {31568696},
	issn = {0956-5663},
	abstract = {Rapid, selective, and ultra-sensitive detection of brain and spinal cord injury markers in bodily fluids is an unmet clinical need. In this work, Polycatecholamine as a rich source of amine moieties was used for single-step fabrication of ultrasensitive immunosensors for the detection of Ubiquitin carboxyl-terminal hydrolase (UCHL-1) biomarker of brain and spinal cord injuries and address the clinical need. The surface of graphene electrodes was modified by electropolymerizing aqueous solution of dopamine (DA) and norepinephrine (NE) monomers for generating polycatecholamines nanofilms on the surface of graphene screen printed electrodes (GSPE) in a single functionalization step. Amine moieties of the polymer allowed immobilization of UCHL-1 antibody on the electrode. The single-step modification of GSPE offered a simple, ultrasensitive, and stable production of immunosensors for the detection of UCHL-1. The operational range of the UCHL-1 immunosensor developed with Polynorepinephrine pNE-modified is 0.1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 1.91 pg mL(-1)), and 1 pg mL(-1) - 10(5) pg mL(-1) (LOD: 0.70 pg mL(-1)) with Polydopamine (pDA) modification, satisfying the clinical range. Both pNE and pDA modified immunosensors, detected UCHL-1 spiked in phosphate buffer saline, artificial cerebrospinal fluid, and serum. Along with the sensitive detections, selective performances were recorded in the above matrices in the presence of interfering neurotransmitters GABA and Glutamate as well as glial fibrillary acidic protein (GFAP). Upon testing clinical samples of spinal cord injury patients and healthy controls, both pNE and pDA immunosensors, delivered a comparable response for UCHL-1, thereby, making immunosensors useful for clinical settings.},
	keywords = {Immunosensor; spinal cord injury; polydopamine (PDA); Poly-norepinephrine (pNE); Ubiquitin carboxyl terminal hydrolase (UCHL-1)},
	year = {2019},
	eissn = {1873-4235},
	orcid-numbers = {Sen, Arindom/0000-0002-8994-8601}
}

@article{MTMT:27598132,
	title = {Performance Evaluation of a Multiplex Assay for Simultaneous Detection of Four Clinically Relevant Traumatic Brain Injury Biomarkers},
	url = {https://m2.mtmt.hu/api/publication/27598132},
	author = {Korley, Frederick K and Yue, John K and Wilson, David H and Hrusovsky, Kevin and Diaz-Arrastia, Ramon and Ferguson, Adam R and Yuh, Esther L and Mukherjee, Pratik and Wang, Kevin K W and Valadka, Alex B and Puccio, Ava M and Okonkwo, David O and Manley, Geoffrey T},
	doi = {10.1089/neu.2017.5623},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {36},
	unique-id = {27598132},
	issn = {0897-7151},
	year = {2019},
	eissn = {1557-9042},
	pages = {182-187}
}

@article{MTMT:30749104,
	title = {Application of the cerebral edema monitor on cardiopulmonary bypass in infants},
	url = {https://m2.mtmt.hu/api/publication/30749104},
	author = {Lan, Jiaming and Wu, Linfeng and Tan, Xingqin and Xiang, Li and Guo, Chunbao},
	doi = {10.1080/02699052.2019.1641746},
	journal-iso = {BRAIN INJURY},
	journal = {BRAIN INJURY},
	volume = {33},
	unique-id = {30749104},
	issn = {0269-9052},
	abstract = {A diagnostic accuracy study was adopted to evaluate the ability of Cerebral edema monitor by comparing the index test results with those of the reference standard. The serum levels of astrocyte S100 protein and neuron-specific enolase (NSE) were determined. Changes in the cerebral electrical impedance coefficient (CEIC) was detected with the BORN-BE monitor. The left- and right-sided CEIC values, serum levels of S100, and serum NSE in the CPB group significantly increased from the beginning to the end of the operation (P < .05). Furthermore, left and right-sided CEIC values, serum levels of S100, and serum NSE in the CPB-B group were significantly higher than those of the CPB-A group (P < .05). Detection rates of cerebral edema in the CPB-B group at the 24 h post-operative time point were significantly higher than those in the CPB-A group (P < .05). The degree of brain damage is positively correlated with the CPB and aortic cross-clamping. CEIC is a sensitive index reflecting brain damage during CPB in infants.},
	keywords = {Infant; brain damage; cardiopulmonary bypass; cerebral electrical impedance coefficient},
	year = {2019},
	eissn = {1362-301X},
	pages = {1379-1384}
}

@article{MTMT:30749105,
	title = {The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus},
	url = {https://m2.mtmt.hu/api/publication/30749105},
	author = {Li, Xue and Sun, Jingjing and Mu, Rong and Gan, Yuzhou and Wang, Guanying and He, Jing and Yi, Li and Wang, Qingwen and Sun, Xiaolin and Li, Zhanguo},
	journal-iso = {CLIN EXP RHEUMATOL},
	journal = {CLINICAL AND EXPERIMENTAL RHEUMATOLOGY},
	volume = {37},
	unique-id = {30749105},
	issn = {0392-856X},
	abstract = {ObjectiveTo identify specific cerebrospinal fluid (CSF) biomarkers for the diagnosis and disease severity evaluation of neuropsychiatric systemic lupus erythematosus (NPSLE).MethodsPatients presented with neuropsychiatric symptoms were recruited and categorised as 36 NPSLE, 19 SLE controls, 4 other connective tissue disease (CTD) controls and 10 nervous system disorder (NSD) controls. The NPSLE group consisted of severe NPSLE (sNPSLE) and mild NPSLE (mNPSLE). Potential biomarkers were determined by Luminex multiplex assay and enzyme-linked immunosorbent assay.Results1) Among a variety of neurological disease-related proteins, only ubiquitin carboxyl hydrolase L1 (UCH-L1) levels were significantly elevated in the CSF samples of sNPSLE patients compared with those of mNPSLE patients (p=0.020) and SLE controls (p=0.037). CSF UCH-L1 levels were significantly positively correlated with SLE disease activity index and overlap number of NPSLE manifestations. 2) CSF anti-UCH-L1 autoantibodies were significantly elevated in patients with NPSLE in comparison to all of the control groups, with a sensitivity of 53% and a specificity of 91% for NPSLE. CSF anti-UCH-L1 levels were associated with organ involvement and were positively correlated with serum anti-UCH-L1 levels in the NPSLE patients (r=0.4551, p=0.0382).ConclusionAnti-UCH-L1 is a promising CSF biomarker for NPSLE diagnosis with high specificity, and the elevated levels of CSF UCH-L1 reflect the clinical severity of NPSLE. The elevation of UCH-L1 and its autoantibody in NPSLE patients showed us novel aetiological insights on NPSLE.},
	keywords = {neuropsychiatric systemic lupus erythematosus; UCH-L1; anti-UCH-L1},
	year = {2019},
	eissn = {1593-098X},
	pages = {474-480}
}

@article{MTMT:31568798,
	title = {UCH-L1 is a Poor Serum Biomarker of Murine Traumatic Brain Injury After Polytrauma},
	url = {https://m2.mtmt.hu/api/publication/31568798},
	author = {Morris, Mackenzie C. and Bercz, Aron and Niziolek, Grace M. and Kassam, Farzaan and Veile, Rose and Friend, Lou Ann and Pritts, Timothy A. and Makley, Amy T. and Goodman, Michael D.},
	doi = {10.1016/j.jss.2019.06.023},
	journal-iso = {J SURG RES},
	journal = {JOURNAL OF SURGICAL RESEARCH},
	volume = {244},
	unique-id = {31568798},
	issn = {0022-4804},
	abstract = {Background: Several serum biomarkers have been studied to diagnose incidence and severity of traumatic brain injury (TBI), but a reliable biomarker in TBI has yet to be identified. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) has been proposed as a biomarker in clinical and preclinical studies, largely in the setting of isolated TBI or concussion. The aim of this study was to evaluate the performance of UGH-L1 as a serum biomarker in the setting of polytrauma and TBI.Methods: Multiple variations of murine TBI and polytrauma models were used to evaluate serum biomarkers. The different models included TBI with and without hemorrhagic shock and resuscitation, isolated extremity vascular ligation, extremity ischemia/reperfusion, and blunt tail injury. Blood was drawn at intervals after injury, and serum levels of neuronspecific enolase, UGH-L1, creatine kinase, and syndecan-1 were evaluated by enzyme-linked immunosorbent assay.Results: UGH-L1 levels were not significantly different between TBI, tail injury, and sham TBI. By contrast, neuron-specific enolase levels were increased in TBI mice compared with tail injury and sham TBI mice. UGH-L1 levels increased regardless of TBI status at 30 min and 4 h after hemorrhagic shock and resuscitation. In mice that underwent femoral artery cannulation followed by hemorrhagic shock/resuscitation, UGH-L1 levels were significantly elevated compared with shock sham mice at 4 h (3158 +/- 2168 pg/mL, 4 h shock versus 0 +/- 0 pg/mL, 4 h shock sham; P < 0.01) and at 24 h (3253 +/- 2954 pg/mL, 24 h shock versus 324 +/- 482 pg/mL, 24 h shock sham; P = 0.03). No differences were observed in UGH-L1 levels between the sham shock and the arterial ligation, vein ligation, or extremity ischemia/reperfusion groups at any time point. Similar to UGH-L1, creatine kinase was elevated only after shock compared with sham mice at 4, 24, and 72 h after injury.Conclusions: Our study demonstrates that UGH-L1 is not a specific marker for TBI but is elevated in models that induce central and peripheral nerve ischemia. Given the increase in UGH-L1 levels observed after hemorrhagic shock, we propose that UGH-L1 may be a useful adjunct in quantifying severity of shock or global ischemia rather than as a specific marker of TBI. (C) 2019 Elsevier Inc. All rights reserved.},
	keywords = {hemorrhagic shock; TRAUMA; TBI; UGH-L1},
	year = {2019},
	eissn = {1095-8673},
	pages = {63-68}
}

@article{MTMT:30701648,
	title = {TBIcare Investigators' Response to Papa and Wang (doi: 10:1089/neu.2017.5030): Raising the Bar for Traumatic Brain Injury Biomarker Research: Methods Make a Difference},
	url = {https://m2.mtmt.hu/api/publication/30701648},
	author = {Posti, Jussi P. and Takala, Riikka S. K. and Tenovuo, Olli},
	doi = {10.1089/neu.2017.5209},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {36},
	unique-id = {30701648},
	issn = {0897-7151},
	year = {2019},
	eissn = {1557-9042},
	pages = {1680-1681}
}

@article{MTMT:30487573,
	title = {Biomarkers in acute brain trauma: A narrative review},
	url = {https://m2.mtmt.hu/api/publication/30487573},
	author = {Quinones-Ossa, G. A. and Padilla-Zambrano, H. and Pal, R. and Ghosh, A. and Moscote-Salazar, L. R. and Kumar, Kiran V. A. and Agrawal, A.},
	doi = {10.4103/2221-6189.250370},
	journal-iso = {J ACUTE DIS},
	journal = {JOURNAL OF ACUTE DISEASE},
	volume = {8},
	unique-id = {30487573},
	issn = {2221-6189},
	abstract = {Biomarkers have been used to diagnose, prognose, evaluate, and identify the severity and outcomes in traumatic brain injury (TBI) patients. This study explored if it is possible to predict the outcome of TBI patients by estimating the biomarkers in cerebrospinal fluid and serum. We searched data bases and literature about biomarkers, and found forty epidemiologic studies from 92 potentially relevant articles. However, limited data are available about postanoxic encephalopathy. It showed that presently, neurofilament, S100B, glial fibrillary acidic protein, and ubiquitin carboxyl terminal hydrolase-L1 seemed to have the best potential as diagnostic biomarkers for distinguishing focal and diffuse injury, whereas C-Tau, neuron-specific enolase, S100B, glial fibrillary acidic protein, and spectrin breakdown products appear to be candidates for reflective biomarkers of TBI. Point-of-care biomarkers are needed in TBI which is one of the most important additional risk factors in road traffic injuries. In a holistic approach, more researches about biomarkers of TBI are required. These biomarkers are very useful for treatment of patients with TBI.},
	keywords = {Brain Injuries; TRAUMA; Serum markers; BIOLOGIC MARKERS; Head injuries; cerebrospinal fluids},
	year = {2019},
	pages = {1-6}
}

@article{MTMT:30725890,
	title = {Stability of Blood Biomarkers of Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/30725890},
	author = {Rezaii, Paymon Garakani and Grant, Gerald Arthur and Zeineh, Michael Maroun and Richardson, Kara Janice and Coburn, Maria Lynn and Bet, Anthony Marco and Weber, Art and Jiang, Bin and Li, Ying and Ubungen, Kristine and Routh, Gay and Wheatcroft, Alex Marie and Paulino, Amy Devine and Hayes, Ronald Lawrence and Steinberg, Gary Kenneth and Wintermark, Max},
	doi = {10.1089/neu.2018.6053},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {36},
	unique-id = {30725890},
	issn = {0897-7151},
	abstract = {Blood biomarker tests were recently approved for clinical diagnosis of traumatic brain injury (TBI), yet there are still fundamental questions that need attention. One such question is the stability of putative biomarkers in blood over the course of several days after injury if the sample is unable to be processed into serum or plasma and stored at low temperatures. Blood may not be able to be stored at ultra-low temperatures in austere combat or sports environments. In this prospective study of 20 adult patients with positive head computed tomography imaging findings, the stability of three biomarkers (glial fibrillary acidic protein [GFAP], ubiquitin C-terminal hydrolase-L1 [UCH-L1], and S100 calcium binding protein B [S100B]) in whole blood and in serum stored at 4-5 degrees C was evaluated over the course of 72 h after blood collection. The amount of time whole blood and serum were refrigerated had no significant effect on GFAP concentration in plasma obtained from whole blood and in serum (p = 0.6256 and p = 0.3687, respectively), UCH-L1 concentration in plasma obtained from whole blood and in serum (p = 0.0611 and p = 0.5189, respectively), and S100B concentration in serum (p = 0.4663). Concentration levels of GFAP, UCH-L1, and S100B in blood collected from patients with TBI were found to be stable at 4-5 degrees C for at least 3 days after blood draw. This study suggests that the levels of the three diagnostic markers above are still valid for diagnostic TBI tests if the sample is stored in 4-5 degrees C refrigerated conditions.},
	keywords = {STABILITY; Biomarkers; traumatic brain injury},
	year = {2019},
	eissn = {1557-9042},
	pages = {2407-2416}
}

@article{MTMT:30651257,
	title = {Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation},
	url = {https://m2.mtmt.hu/api/publication/30651257},
	author = {Rubenstein, Richard and Sharma, Deep R. and Chang, Binggong and Oumata, Nassima and Came, Morgane and Vaucelle, Use and Lindberg, Mattias F. and Chiu, Allen and Wisniewski, Thomas and Wang, Kevin K. W. and Meijer, Laurent},
	doi = {10.3389/fneur.2019.00124},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {10},
	unique-id = {30651257},
	issn = {1664-2295},
	abstract = {Traumatic brain injury (TBI) is a risk factor for a group of neurodegenerative diseases termed tauopathies, which includes Alzheimer's disease and chronic traumatic encephalopathy (CTE). Although TBI is stratified by impact severity as either mild (m), moderate or severe, mTBI is the most common and the most difficult to diagnose. Tauopathies are pathologically related by the accumulation of hyperphosphorylated tau (P-tau) and increased total tau (T-tau). Here we describe: (i) a novel human tau-expressing transgenic mouse model, TghTau/PS1, to study repetitive mild closed head injury (rmCHI), (ii) quantitative comparison of T-tau and P-tau from brain and plasma in TghTau/PS1 mice over a 12 month period following rmCHI (and sham), (iii) the usefulness of P-tau as an early- and late-stage blood-based biochemical biomarker for rmCHI, (iii) the influence of kinase-targeted therapeutic intervention on rmCHI-associated cognitive deficits using a combination of lithium chloride (UCI) and R-roscovitine (ros), and (iv) correlation of behavioral and cognitive changes with concentrations of the brain and blood-based T-tau and P-tau. Compared to sham-treated mice, behavior changes and cognitive deficits of rrriCHI-treated TghTau/PS1 mice correlated with increases in both cortex and plasma T-tau and P-tau levels over 12 months. In addition, T-tau, but more predominantly P-tau, levels were significantly reduced in the cortex and plasma by LiCI + ros approaching the biomarker levels in sham and drug-treated sham mice (the drugs had only modest effects on the T-tau and P-tau levels in sham mice) throughout the 12 month study period. Furthermore, although we also observed a reversal of the abnormal behavior and cognitive deficits in the drug-treated rmCHI mice (compared to the untreated rmCHI mice) throughout the time course, these drug-treated effects were most pronounced up until 10 and 12 months where the abnormal behavior and cognition deficits began to gradually increase. These studies describe: (a) a translational relevant animal model for TBI-linked tauopathies, and (b) utilization of T-tau and P-tau as rmCHl biomarkers in plasma to monitor novel therapeutic strategies and treatment regimens for these neurodegenerative diseases.},
	keywords = {cognition; traumatic brain injury; roscovitine; Lithium Chloride; repetitive mild closed head injury; TghTau/PS1 transgenic mice; total tau and phosphorylated tau; brain and blood-based biomarkers},
	year = {2019},
	eissn = {1664-2295},
	orcid-numbers = {Wisniewski, Thomas/0000-0002-3379-8966}
}

@article{MTMT:30725729,
	title = {A Serum Protein Biomarker Panel Improves Outcome Prediction in Human Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/30725729},
	author = {Thelin, Eric and Al Nimer, Faiez and Frostell, Arvid and Zetterberg, Henrik and Blennow, Kaj and Nystrom, Harriet and Svensson, Mikael and Bellander, Bo-Michael and Piehl, Fredrik and Nelson, David W.},
	doi = {10.1089/neu.2019.6375},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {36},
	unique-id = {30725729},
	issn = {0897-7151},
	abstract = {Brain-enriched protein biomarkers of tissue fate are being introduced clinically to aid in traumatic brain injury (TBI) management. The aim of this study was to determine how concentrations of six different protein biomarkers, measured in samples collected during the first weeks after TBI, relate to injury severity and outcome. We included neurocritical care TBI patients that were prospectively enrolled from 2007 to 2013, all having one to three blood samples drawn during the first 2 weeks. The biomarkers analyzed were S100 calcium-binding protein B (S100B), neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1), tau, and neurofilament-light (NF-L). Glasgow Outcome Score (GOS) was assessed at 12 months. In total, 172 patients were included. All serum markers were associated with injury severity as classified on computed tomography scans at admission. Almost all biomarkers outperformed other known outcome predictors with higher levels the first 5 days, correlating with unfavorable outcomes, and UCH-L1 (0.260, pseduo-R-2) displaying the best discrimination in univariate analyses. After adjusting for acknowledged TBI outcome predictors, GFAP and NF-L added most independent information to predict favorable/unfavorable GOS, improving the model from 0.38 to 0.51 pseudo-R-2. A correlation matrix indicated substantial covariance, with the strongest correlation between UCH-L1, GFAP, and tau (r = 0.827-0.880). Additionally, the principal component analysis exhibited clustering of UCH-L1 and tau, as well as GFAP, S100B, and NSE, which was separate from NF-L. In summary, a panel of several different protein biomarkers, all associated with injury severity, with different cellular origin and temporal trajectories, improve outcome prediction models.},
	keywords = {traumatic brain injury; Functional outcome; neuroradiology; Protein biomarkers; injury severity assessment; serum analysis},
	year = {2019},
	eissn = {1557-9042},
	pages = {2850-2862}
}

@article{MTMT:30522374,
	title = {Novel Metabolomic Comparison of Arterial and Jugular Venous Blood in Severe Adult Traumatic Brain Injury Patients and the Impact of Pentobarbital Infusion},
	url = {https://m2.mtmt.hu/api/publication/30522374},
	author = {Wolahan, Stephanie M. and Lebby, Elliott and Mao, Howard C. and McArthur, David and Real, Courtney and Vespa, Paul and Braas, Daniel and Glenn, Thomas C.},
	doi = {10.1089/neu.2018.5674},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {36},
	unique-id = {30522374},
	issn = {0897-7151},
	abstract = {Treatment of severe traumatic brain injury (TBI) in the intensive care unit focuses on controlling intracranial pressure, ensuring sufficient cerebral perfusion, and monitoring for secondary injuries. However, there are limited prognostic tools and no biomarkers or tests of the evolving neuropathology. Metabolomics has the potential to be a powerful tool to indirectly monitor evolving dysfunctional metabolism. We compared metabolite levels in simultaneously collected arterial and jugular venous samples in acute TBI patients undergoing intensive care as well as in healthy control volunteers. Our results show that, first, many circulating metabolites are decreased in TBI patients compared with healthy controls days after injury; both proline and hydroxyproline were depleted by 60% compared with healthy controls, as was gluconate. Second, both arterial and jugular venous plasma metabolomic analysis separates TBI patients from healthy controls and shows that distinct combinations of metabolites are driving the group separation in the two blood types. Third, TBI patients under heavy sedation with pentobarbital at the time of blood collection were discernibly different from patients not receiving pentobarbital. These results highlight the importance of accounting for medications in metabolomics analysis. Jugular venous plasma metabolomics shows potential as a minimally invasive tool to identify and study dysfunctional cerebral metabolism after TBI.},
	keywords = {human; PENTOBARBITAL; metabolomics; jugular venous blood},
	year = {2019},
	eissn = {1557-9042},
	pages = {212-221}
}

@article{MTMT:30529128,
	title = {Concussion Biomarkers Assessed in Collegiate Student-Athletes (BASICS) I Normative study},
	url = {https://m2.mtmt.hu/api/publication/30529128},
	author = {Asken, Breton M. and Bauer, Russell M. and DeKosky, Steven T. and Houck, Zachary M. and Moreno, Charles C. and Jaffee, Michael S. and Weber, Arthur G. and Clugston, James R.},
	doi = {10.1212/WNL.0000000000006613},
	journal-iso = {NEUROLOGY},
	journal = {NEUROLOGY},
	volume = {91},
	unique-id = {30529128},
	issn = {0028-3878},
	abstract = {Objective},
	year = {2018},
	eissn = {1526-632X},
	pages = {E2109-E2122}
}

@article{MTMT:30529129,
	title = {Goal-Directed Oxygen Delivery During Cardiopulmonary Bypass: Can This Perfusion Strategy Improve Biochemical and Clinical Neurologic Outcomes?},
	url = {https://m2.mtmt.hu/api/publication/30529129},
	author = {Awad, Hamdy and Essandoh, Michael},
	doi = {10.1053/j.jvca.2018.07.052},
	journal-iso = {J CARDIOTHOR VASC AN},
	journal = {JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA},
	volume = {32},
	unique-id = {30529129},
	issn = {1053-0770},
	year = {2018},
	eissn = {1532-8422},
	pages = {2493-2494}
}

@article{MTMT:30528945,
	title = {Relationship of calcitonin gene-related peptide with disease progression and prognosis of patients with severe traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/30528945},
	author = {Chen, Li-Xiong and Zhang, Wei-Feng and Wang, Ming and Jia, Pi-Feng},
	doi = {10.4103/1673-5374.238619},
	journal-iso = {NEUR REG RES},
	journal = {NEURAL REGENERATION RESEARCH},
	volume = {13},
	unique-id = {30528945},
	issn = {1673-5374},
	abstract = {Calcitonin gene-related peptide (CGRP) has been implicated in multiple functions across many bioprocesses; however, whether CGRP is associated with severe traumatic brain injury (TBI) remains poorly understood. In this study, 96 adult patients with TBI (enrolled from September 2015 to December 2016) were divided into a mild/moderate TBI group (36 males and 25 females, aged 38 +/- 13 years) and severe TBI group (22 males and 13 females, aged 38 +/- 11 years) according to Glasgow Coma Scale scores. In addition, 25 healthy individuals were selected as controls (15 males and 10 females, aged 39 +/- 13 years). Radioimmunoassay was used to detect serum levels of CGRP and endothelin-1 at admission and at 12, 24, 48, 72 hours, and 7 days after admission. CGRP levels were remarkably lower, but endothelin-1 levels were obviously higher in the severe TBI group compared with mild/moderate TBI and control groups. Levels of CGRP were remarkably lower, but endothelin-1 levels were obviously higher in deceased patients compared with patients who survived. Survival analysis and logistic regression showed that both CGRP and endothelin-1 levels were associated with patient mortality, with each serving as an independent risk factor for 6-month mortality of severe TBI patients. Moreover, TBI patients with lower serum CGRP levels had a higher risk of death. Thus, our retrospective analysis demonstrates the potential utility of CGRP as a new biomarker, monitoring method, and therapeutic target for TBI.},
	keywords = {MORTALITY; calcitonin gene-related peptide; Nerve Regeneration; endothelin-1; neural regeneration; Critical Care Medicine; Severe traumatic brain injury; prognosis biomarkers; dynamic serum levels},
	year = {2018},
	eissn = {1876-7958},
	pages = {1782-1786}
}

@article{MTMT:27669184,
	title = {Looking for novel, brain-derived, peripheral biomarkers of neurological disorders},
	url = {https://m2.mtmt.hu/api/publication/27669184},
	author = {Chmielewska, N and Szyndler, J and Makowska, K and Wojtyna, D and Maciejak, P and Płaźnik, A},
	doi = {10.1016/j.pjnns.2018.02.002},
	journal-iso = {NEUROL NEUROCHIR POL},
	journal = {NEUROLOGIA I NEUROCHIRURGIA POLSKA},
	volume = {52},
	unique-id = {27669184},
	issn = {0028-3843},
	year = {2018},
	eissn = {1897-4260},
	pages = {318-325}
}

@article{MTMT:30529131,
	title = {Serum ST2 as a potential prognostic biomarker for traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/30529131},
	author = {Du, Quan and Weng, Jian-Feng and Luo, Li-Feng and Cen, Meng and Yu, Wen-Hua and Zheng, Yong-Ke and Hu, Wei and Pan, Jian-Wei and Dong, Xiao-Qiao},
	doi = {10.1016/j.cca.2018.09.035},
	journal-iso = {CLIN CHIM ACTA},
	journal = {CLINICA CHIMICA ACTA},
	volume = {487},
	unique-id = {30529131},
	issn = {0009-8981},
	abstract = {Background: ST2, a receptor of interleukin-33, is involved in inflammation. We discerned the relationship between serum soluble ST2 (sST2) concentrations, inflammation, severity and prognosis following traumatic brain injury (TBI).},
	keywords = {Inflammation; Prognosis; traumatic brain injury; SEVERITY; ST2},
	year = {2018},
	eissn = {1873-3492},
	pages = {145-152}
}

@article{MTMT:27341898,
	title = {Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial},
	url = {https://m2.mtmt.hu/api/publication/27341898},
	author = {Hellewell, Sarah C and Mondello, Stefania and Conquest, Alison and Shaw, Gerry and Madorsky, Irina and Deng, Jay V and Little, Lorraine and Kobeissy, Firas and Bye, Nicole and Bellomo, Rinaldo and Cooper, David J and Vallance, Shirley and Board, Jasmine and Morganti-Kossmann, Maria C},
	doi = {10.1097/CCM.0000000000002938},
	journal-iso = {CRIT CARE MED},
	journal = {CRITICAL CARE MEDICINE},
	volume = {46},
	unique-id = {27341898},
	issn = {0090-3493},
	year = {2018},
	eissn = {1530-0293},
	pages = {554-561}
}

@article{MTMT:27341894,
	title = {Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disability},
	url = {https://m2.mtmt.hu/api/publication/27341894},
	author = {Hughes, Christopher G and Patel, Mayur B and Brummel, Nathan E and Thompson, Jennifer L and McNeil, J Brennan and Pandharipande, Pratik P and Jackson, James C and Chandrasekhar, Rameela and Ware, Lorraine B and Ely, E Wesley and Girard, Timothy D},
	doi = {10.1007/s00134-018-5120-1},
	journal-iso = {INTENS CARE MED},
	journal = {INTENSIVE CARE MEDICINE},
	volume = {44},
	unique-id = {27341894},
	issn = {0342-4642},
	year = {2018},
	eissn = {1432-1238},
	pages = {345-355}
}

@article{MTMT:32464248,
	title = {Biomarkers in traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/32464248},
	author = {Ilginel, M.T. and Tunay, D.L. and Güneş, Y.},
	journal-iso = {ANESTEZI DERGESI},
	journal = {ANESTEZI DERGESI},
	volume = {26},
	unique-id = {32464248},
	issn = {1300-0578},
	year = {2018},
	pages = {105-119}
}

@{MTMT:31406431,
	title = {Blood and cerebrospinal fluid biomarkers},
	url = {https://m2.mtmt.hu/api/publication/31406431},
	author = {Kawata, Keisuke and Tierney, Ryan and Langford, Dianne},
	booktitle = {SPORTS NEUROLOGY},
	doi = {10.1016/B978-0-444-63954-7.00022-7},
	unique-id = {31406431},
	abstract = {Sports-related traumatic brain injuries (TBIs) range in severity from severe to subconcussive. Although technologies exist for clinical diagnosis of more severe injuries, methods for diagnosis of milder forms of brain injury are limited. Developing objective measures to indicate pathogenic processes after a suspected mild TBI is challenging for multiple reasons. The field of biomarker discovery for diagnosing TBI continues to expand, with newly identified candidate biomarkers being reported regularly. Brain-specific biomarkers include proteins derived from neurons and glia, and are often measured to assess neural injury and repair, and to predict outcomes. Ideally, changes in biomarker levels should indicate pathologic events and answer critical questions for accurate diagnosis and prognosis. For example, does the presence or a change in the biomarker level suggest greater vulnerability for sustaining a second concussion or show that the window of increased vulnerability has passed? Likewise, do changes in biomarker levels predict postconcussion syndrome or recovery/repair? Although there are numerous promising candidates for fluid biomarkers that may diagnose mild TBI or concussion, none has reached the clinic to date. In this chapter, we will define biomarkers, discuss the importance of understanding their normal and pathologic functions, and outline some considerations for interpreting detection assay results in TBI. We will then review five proposed blood and cerebrospinal fluid biomarkers (tau, neurofilament, ubiquitin carboxyl-terminal hydrolase L1, S100 beta, and glial fibrillary acidic protein) used currently to address TBI. Lastly, we will discuss a future trajectory for developing new, clinically useful fluid biomarkers.},
	keywords = {COMPUTED-TOMOGRAPHY; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; Diffuse axonal injury; Clinical Neurology; NEUROFILAMENT LIGHT; TAU-PROTEIN; S100b protein; C-TERMINAL HYDROLASE-L1; NEUROCHEMICAL AFTERMATH},
	year = {2018},
	pages = {217-233}
}

@article{MTMT:30529133,
	title = {Diagnosis of traumatic brain injury using miRNA signatures in nanomagnetically isolated brain-derived extracellular vesicles},
	url = {https://m2.mtmt.hu/api/publication/30529133},
	author = {Ko, J. and Hemphill, M. and Yang, Z. and Sewell, E. and Na, Y. J. and Sandsmark, D. K. and Haber, M. and Fisher, S. A. and Torre, E. A. and Svane, K. C. and Omelchenko, A. and Firestein, B. L. and Diaz-Arrastia, R. and Kim, J. and Meaney, D. F. and Issadore, D.},
	doi = {10.1039/c8lc00672e},
	journal-iso = {LAB CHIP},
	journal = {LAB ON A CHIP},
	volume = {18},
	unique-id = {30529133},
	issn = {1473-0197},
	abstract = {The accurate diagnosis and clinical management of traumatic brain injury (TBI) is currently limited by the lack of accessible molecular biomarkers that reflect the pathophysiology of this heterogeneous disease. To address this challenge, we developed a microchip diagnostic that can characterize TBI more comprehensively using the RNA found in brain-derived extracellular vesicles (EVs). Our approach measures a panel of EV miRNAs, processed with machine learning algorithms to capture the state of the injured and recovering brain. Our diagnostic combines surface marker-specific nanomagnetic isolation of brain-derived EVs, biomarker discovery using RNA sequencing, and machine learning processing of the EV miRNA cargo to minimally invasively measure the state of TBI. We achieved an accuracy of 99% identifying the signature of injured vs. sham control mice using an independent blinded test set (N = 77), where the injured group consists of heterogeneous populations (injury intensity, elapsed time since injury) to model the variability present in clinical samples. Moreover, we successfully predicted the intensity of the injury, the elapsed time since injury, and the presence of a prior injury using independent blinded test sets (N = 82). We demonstrated the translatability in a blinded test set by identifying TBI patients from healthy controls (AUC = 0.9, N = 60). This approach, which can detect signatures of injury that persist across a variety of injury types and individual responses to injury, more accurately reflects the heterogeneity of human TBI injury and recovery than conventional diagnostics, opening new opportunities to improve treatment of traumatic brain injuries.},
	year = {2018},
	eissn = {1473-0189},
	pages = {3617-3630}
}

@article{MTMT:30528943,
	title = {Integration of Biomarkers Into a Signature Profile of Persistent Traumatic Brain Injury Involving Autoimmune Processes Following Water Hammer Injury From Repetitive Head Impacts},
	url = {https://m2.mtmt.hu/api/publication/30528943},
	author = {Kornguth, Steven and Rutledge, Neal},
	doi = {10.1177/1177271918808216},
	journal-iso = {BIOMARKER INSIGHTS},
	journal = {BIOMARKER INSIGHTS},
	volume = {13},
	unique-id = {30528943},
	issn = {1177-2719},
	abstract = {OBJECTIVES: To assemble an algorithm that will describe a "Signature" predictive of an individual's vulnerability to persistent traumatic brain injury (TBI)},
	keywords = {major histocompatibility complex; autoimmune disease; traumatic brain injury; diffusion tensor imaging; Neuronal glial proteins; Signature of Vulnerability to TBI},
	year = {2018}
}

@article{MTMT:30483411,
	title = {Temporal response profiles of serum ubiquitin C-terminal hydrolase-L1 and the 145-kDa alpha II-spectrin breakdown product after severe traumatic brain injury in children},
	url = {https://m2.mtmt.hu/api/publication/30483411},
	author = {Metzger, Ryan R. and Sheng, Xiaoming and Niedzwecki, Christian M. and Bennett, Kimberly S. and Morita, Denise C. and Zielinski, Brandon and Schober, Michelle E.},
	doi = {10.3171/2018.4.PEDS17593},
	journal-iso = {J NEUROS-PEDIATR},
	journal = {JOURNAL OF NEUROSURGERY - PEDIATRICS},
	volume = {22},
	unique-id = {30483411},
	issn = {1933-0707},
	abstract = {OBJECTIVE Traumatic brain injury (TBI) is the leading cause of acquired disability among children. Brain injury biomarkers may serve as useful diagnostic and prognostic indicators for TBI. Levels of ubiquitin C-terminal hydrolase-L1 (UCH-L1) and the 145-kDa alpha II-spectrin breakdown product (SBDP-145) correlate with outcome in adults after severe TBI. The authors conducted a pilot study of these biomarkers in children after severe TBI to inform future research exploring their utility in this population.},
	keywords = {SERUM; Biomarkers; cerebrospinal fluid; traumatic brain injury; TRAUMA; Pediatric},
	year = {2018},
	eissn = {1933-0715},
	pages = {369-374}
}

@article{MTMT:27604646,
	title = {Traumatic brain injury: classification, models, and markers},
	url = {https://m2.mtmt.hu/api/publication/27604646},
	author = {Najem, Dema and Rennie, Kerry and Ribecco-Lutkiewicz, Maria and Dao, Ly and Haukenfrers, Julie and Liu, Qing and Nzau, Munyao and Fraser, Douglas D and Bani-Yaghoub, Mahmud},
	doi = {10.1139/bcb-2016-0160},
	journal-iso = {BIOCHEM CELL BIOL},
	journal = {BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE},
	volume = {96},
	unique-id = {27604646},
	issn = {0829-8211},
	year = {2018},
	eissn = {1208-6002},
	pages = {391-406}
}

@article{MTMT:30521951,
	title = {Serum biomarkers of neuronal injury in newborns evaluated for selective head cooling: a comparative pilot study},
	url = {https://m2.mtmt.hu/api/publication/30521951},
	author = {Patila, Uday P. and Mally, Pradeep V. and Wachtel, Elena V.},
	doi = {10.1515/jpm-2017-0354},
	journal-iso = {J PERINAT MED},
	journal = {JOURNAL OF PERINATAL MEDICINE},
	volume = {46},
	unique-id = {30521951},
	issn = {0300-5577},
	abstract = {Background: Evaluation of newborns for hypoxic ischemic encephalopathy (HIE) includes laboratory and clinical parameters, as well as amplitude integrated electroencephalogram (aEEG). Based on qualifying criteria, selective head cooling (SHC) is initiated for infants with evidence of moderate to severe HIE. However, some newborns may not qualify for hypothermia therapy based on normal aEEG.},
	keywords = {newborn; glial fibrillary acidic protein; hypoxic ischemic encephalopathy; Therapeutic hypothermia; phosphorylated axonal neurofilament heavy chain; ubiquitin C-terminal hydrolase-1 protein},
	year = {2018},
	eissn = {1619-3997},
	pages = {942-947}
}

@article{MTMT:27350288,
	title = {The diagnostic values of UCH-L1 in traumatic brain injury: A meta-analysis},
	url = {https://m2.mtmt.hu/api/publication/27350288},
	author = {Shahjouei, Shima and Sadeghi-Naini, Mohsen and Yang, Zhihui and Kobeissy, Firas and Rathore, Disa and Shokraneh, Farhad and Blackburn, Spiros and Manley, Geoff T and Wang, Kevin K W},
	doi = {10.1080/02699052.2017.1382717},
	journal-iso = {BRAIN INJURY},
	journal = {BRAIN INJURY},
	volume = {32},
	unique-id = {27350288},
	issn = {0269-9052},
	year = {2018},
	eissn = {1362-301X},
	pages = {1-17}
}

@article{MTMT:27465976,
	title = {Serum concentration of ubiquitin c-terminal hydrolase-L1 in detecting severity of traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/27465976},
	author = {Siahaan, AMP and Japardi, I and Hakim, AA},
	doi = {10.1088/1755-1315/125/1/012207},
	journal-iso = {IOP CONF SER EARTH AND ENVIRON SCI},
	journal = {IOP CONFERENCE SERIES: EARTH AND ENVIRONMENTAL SCIENCE},
	volume = {125},
	unique-id = {27465976},
	issn = {1755-1307},
	year = {2018},
	eissn = {1755-1315}
}

@article{MTMT:27466040,
	title = {Early and rapid detection of UCHL1 in the serum of brain-trauma patients: A novel gold nanoparticle-based method for diagnosing the severity of brain injury},
	url = {https://m2.mtmt.hu/api/publication/27466040},
	author = {Singh, GP and Nigam, R and Tomar, GS and Monisha, M and Bhoi, SK and Arulselvi, S and Sengar, K and Akula, D and Panta, P and Anindya, R},
	doi = {10.1039/c8an00533h},
	journal-iso = {ANALYST},
	journal = {ANALYST},
	volume = {143},
	unique-id = {27466040},
	issn = {0003-2654},
	year = {2018},
	eissn = {1364-5528},
	pages = {3366-3373}
}

@article{MTMT:27341895,
	title = {Overexpression of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in boys with cryptorchidism},
	url = {https://m2.mtmt.hu/api/publication/27341895},
	author = {Toliczenko-Bernatowicz, Dorota and Matuszczak, Ewa and Tylicka, Marzena and Szymanska, Beata and Komarowska, Marta and Gorodkiewicz, Ewa and Debek, Wojciech and Hermanowicz, Adam},
	doi = {10.1371/journal.pone.0191806},
	journal-iso = {PLOS ONE},
	journal = {PLOS ONE},
	volume = {13},
	unique-id = {27341895},
	issn = {1932-6203},
	year = {2018},
	eissn = {1932-6203}
}

@article{MTMT:27350296,
	title = {An update on diagnostic and prognostic biomarkers for traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/27350296},
	author = {Wang, Kevin K and Yang, Zhihui and Zhu, Tian and Shi, Yuan and Rubenstein, Richard and Tyndall, J Adrian and Manley, Geoff T},
	doi = {10.1080/14737159.2018.1428089},
	journal-iso = {EXPERT REV MOL DIAGN},
	journal = {EXPERT REVIEW OF MOLECULAR DIAGNOSTICS},
	volume = {18},
	unique-id = {27350296},
	issn = {1473-7159},
	year = {2018},
	eissn = {1744-8352},
	pages = {165-180}
}

@{MTMT:27466045,
	title = {Biofluid proteomics and biomarkers in traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/27466045},
	author = {Azar, S and Hasan, A and Younes, R and Najdi, F and Baki, L and Ghazale, H and Kobeissy, FH and Zibara, K and Mondello, S},
	booktitle = {Neuroproteomics},
	doi = {10.1007/978-1-4939-6952-4_3},
	unique-id = {27466045},
	year = {2017},
	pages = {45-63}
}

@article{MTMT:26771596,
	title = {Correlation of ubiquitin C terminal hydrolase and S100 beta with cognitive deficits in young adults with mild traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/26771596},
	author = {Dey, Subir and Gangadharan, Jagathlal and Deepika, Akhil and Kumar, J Keshav and Christopher, Rita and Ramesh, Shruthi S and Devi, B Indira and Shukla, Dhaval P},
	doi = {10.4103/neuroindia.NI_884_15},
	journal-iso = {NEUROL INDIA},
	journal = {NEUROLOGY INDIA},
	volume = {65},
	unique-id = {26771596},
	issn = {0028-3886},
	year = {2017},
	eissn = {1998-4022},
	pages = {761-766}
}

@article{MTMT:27103670,
	title = {Effects of andrographolide on postoperative cognitive dysfunction and the association with NF-kappa B/MAPK pathway},
	url = {https://m2.mtmt.hu/api/publication/27103670},
	author = {Ding, Yongbo and Shi, Cunxian and Chen, Linjing and Ma, Piliang and Li, Kezhong and Jin, Jin and Zhang, Qingfeng and Li, Aizhi},
	doi = {10.3892/ol.2017.7088},
	journal-iso = {ONCOL LETT},
	journal = {ONCOLOGY LETTERS},
	volume = {14},
	unique-id = {27103670},
	issn = {1792-1074},
	year = {2017},
	eissn = {1792-1082},
	pages = {7367-7373}
}

@article{MTMT:27466043,
	title = {Management of severe traumatic brain injury (first 24 hours)},
	url = {https://m2.mtmt.hu/api/publication/27466043},
	author = {Geeraerts, T and Velly, L and Abdennour, L and Asehnoune, K and Audibert, G and Bouzat, P and Bruder, N and Carrillon, R and Cottenceau, V and Cotton, F and Courtil-Teyssedre, S and Dahyot-Fizelier, C and Dailler, F and David, J-S and Engrand, N and Fletcher, D and Francony, G and Gergelé, L and Ichai, C and Javouhey, É and Leblanc, P-E and Lieutaud, T and Meyer, P and Mirek, S and Orliaguet, G and Proust, F and Quintard, H and Ract, C and Srairi, M and Tazarourte, K and Vigué, B and Payen, J-F},
	doi = {10.1016/j.jeurea.2017.04.007},
	journal-iso = {JOURNAL EUROPEEN DES URGENCES ET DE REANIMATION},
	journal = {JOURNAL EUROPEEN DES URGENCES ET DE REANIMATION},
	volume = {29},
	unique-id = {27466043},
	issn = {2211-4238},
	year = {2017},
	pages = {167-192}
}

@{MTMT:27465687,
	title = {The Use of Blood-Based Biomarkers to Improve the Design of Clinical Trials of Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/27465687},
	author = {Glushakova, OY and Glushakov, AV and Mannix, R and Miller, ER and Valadka, AB and Hayes, RL},
	booktitle = {Handbook of Neuroemergency Clinical Trials: Second Edition},
	doi = {10.1016/B978-0-12-804064-5.00008-4},
	publisher = {Elsevier Inc.},
	unique-id = {27465687},
	year = {2017},
	pages = {139-166}
}

@article{MTMT:26938869,
	title = {Prognostic utility of neuroinjury biomarkers in post out-of-hospital cardiac arrest (OHCA) patient management},
	url = {https://m2.mtmt.hu/api/publication/26938869},
	author = {Gul, S S and Huesgen, K W and Wang, K K and Mark, K and Tyndall, J A},
	doi = {10.1016/j.mehy.2017.06.016},
	journal-iso = {MED HYPOTHESES},
	journal = {MEDICAL HYPOTHESES},
	volume = {105},
	unique-id = {26938869},
	issn = {0306-9877},
	year = {2017},
	eissn = {1532-2777},
	pages = {34-47}
}

@book{MTMT:34496720,
	title = {The handbook of biomarkers},
	url = {https://m2.mtmt.hu/api/publication/34496720},
	isbn = {9781493974313},
	author = {Jain, K.K.},
	doi = {10.1007/9781493974313},
	publisher = {Springer US},
	unique-id = {34496720},
	year = {2017},
	pages = {1-760}
}

@article{MTMT:26771613,
	title = {Utility of Serum Biomarkers in the Diagnosis and Stratification of Mild Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/26771613},
	author = {Lewis, Lawrence M and Schloemann, Derek T and Papa, Linda and Fucetola, Robert P and Bazarian, Jeffrey and Lindburg, Miranda and Welch, Robert D},
	doi = {10.1111/acem.13174},
	journal-iso = {ACAD EMERG MED},
	journal = {ACADEMIC EMERGENCY MEDICINE},
	volume = {24},
	unique-id = {26771613},
	issn = {1069-6563},
	year = {2017},
	eissn = {1553-2712},
	pages = {710-720}
}

@article{MTMT:27103672,
	title = {Biomarkers Associated with the Outcome of Traumatic Brain Injury Patients},
	url = {https://m2.mtmt.hu/api/publication/27103672},
	author = {Lorente, Leonardo},
	doi = {10.3390/brainsci7110142},
	journal-iso = {BRAIN SCI},
	journal = {BRAIN SCIENCES},
	volume = {7},
	unique-id = {27103672},
	year = {2017},
	eissn = {2076-3425},
	orcid-numbers = {Lorente, Leonardo/0000-0003-4902-4065}
}

@article{MTMT:26584142,
	title = {Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase-L1 Are Not Specific Biomarkers for Mild CT-Negative Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/26584142},
	author = {Posti, Jussi P and Hossain, Iftakher and Takala, Riikka S K and Liedes, Hilkka and Newcombe, Virginia and Outtrim, Joanne and Katila, Ari J and Frantzen, Janek and Ala-Seppala, Henna and Coles, Jonathan P and Kyllonen, Anna and Maanpaa, Henna-Riikka and Tallus, Jussi and Hutchinson, Peter J and van Gils, Mark and Menon, David K and Tenovuo, Olli and TBIcare, Investigators},
	doi = {10.1089/neu.2016.4442},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {34},
	unique-id = {26584142},
	issn = {0897-7151},
	year = {2017},
	eissn = {1557-9042},
	pages = {1427-1438}
}

@{MTMT:31882281,
	title = {Neuroproteomics Studies: Challenges and Updates},
	url = {https://m2.mtmt.hu/api/publication/31882281},
	author = {Ramadan, Naify and Ghazale, Hussein and El-Sayyad, Mohammad and El-Haress, Mohamad and Kobeissy, Firas H.},
	booktitle = {Neuroproteomics},
	doi = {10.1007/978-1-4939-6952-4_1},
	unique-id = {31882281},
	abstract = {The Human Genome Project in 2003 has resulted in the complete sequence of similar to 99% of the human genome paving the road for the Human Proteome Project (HPP) assessing the full characterization of the translated protein map of the 20,300 protein-coding genes. Consequently, the emerging of the proteomics field has successfully been adopted as the method of choice for the proteome characterization. Proteomics is a term that is used to encompass multidisciplinary approaches combining different technologies that aim to study the entire spectrum of protein changes at a specific physiological condition. Proteomics research has shown excellent outcomes in different fields, among which is neuroscience; however, the complexity of the nervous systems necessitated the genesis of a new subdiscipline of proteomics termed as "neuroproteomics." Neuroproteomics studies involve assessing the quantitative and qualitative aspects of nervous system components encompassing global dynamic events underlying various brain-related disorders ranging from neuropsychiatric disorders, degenerative disorders, mental illness, and most importantly brain-specific neurotrauma-related injuries. In this introductory chapter, we will provide a brief historical perspective on the field of neuroproteomics. In doing so, we will highlight on the recent applications of neuroproteomics in the areas of neurotrauma, an area that has benefitted from neuroproteomics in terms of biomarker research, spatiotemporal injury mechanism, and its use to translate its findings from experimental settings to human translational applications. Importantly, this chapter will include some recommendation to the general studies in the area of neuroproteomics and the need to move from this field from being a descriptive, hypothesis-free approach to being an independent mature scientific discipline.},
	keywords = {QUANTITATIVE-ANALYSIS; CEREBROSPINAL-FLUID; Systems biology; protein expression; Human Genome Project; proteomics; Biomarker discovery; TRAUMATIC BRAIN-INJURY; IMS; Neuroproteomics; Biochemistry & Molecular Biology; Biochemical Research Methods; TOP-DOWN PROTEOMICS; IMAGING MASS-SPECTROMETRY; Antibody array; High-throughput immunoblotting; Imaging mass spectrometry (MS)},
	year = {2017},
	pages = {3-19},
	orcid-numbers = {Ramadan, Naify/0000-0001-7339-0263}
}

@article{MTMT:27466044,
	title = {Determinants of prognosis in neurocatastrophes},
	url = {https://m2.mtmt.hu/api/publication/27466044},
	author = {Sharma, K and Stevens, RD},
	doi = {10.1016/B978-0-444-63600-3.00021-0},
	journal-iso = {HANDB CLIN NEUROL},
	journal = {HANDBOOK OF CLINICAL NEUROLOGY},
	volume = {140},
	unique-id = {27466044},
	issn = {0072-9752},
	year = {2017},
	eissn = {2212-4152},
	pages = {379-395}
}

@article{MTMT:3248575,
	title = {Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain injury Dynamics: A Systematic Review},
	url = {https://m2.mtmt.hu/api/publication/3248575},
	author = {Thelin, EP and Zeiler, FA and Ercole, A and Mondello, S and Büki, András and Bellander, BM and Helmy, A and Menon, DK and Nelson, DW},
	doi = {10.3389/fneur.2017.00300},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {8},
	unique-id = {3248575},
	issn = {1664-2295},
	year = {2017},
	eissn = {1664-2295}
}

@article{MTMT:26757897,
	title = {Metal Nanoparticles for the Treatment and Diagnosis of Neurodegenerative Brain Diseases},
	url = {https://m2.mtmt.hu/api/publication/26757897},
	author = {Vio, Valentina and Jose, Marchant Maria and Araya, Eyleen and Kogan, Marcelo J},
	doi = {10.2174/1381612823666170105152948},
	journal-iso = {CURR PHARM DESIGN},
	journal = {CURRENT PHARMACEUTICAL DESIGN},
	volume = {23},
	unique-id = {26757897},
	issn = {1381-6128},
	year = {2017},
	eissn = {1873-4286},
	pages = {1916-1926}
}

@article{MTMT:26539415,
	title = {The Next Generation of Biomarker Research in Spinal Cord Injury},
	url = {https://m2.mtmt.hu/api/publication/26539415},
	author = {Ydens, Elke and Palmers, Ilse and Hendrix, Sven and Somers, Veerle},
	doi = {10.1007/s12035-016-9757-x},
	journal-iso = {MOL NEUROBIOL},
	journal = {MOLECULAR NEUROBIOLOGY},
	volume = {54},
	unique-id = {26539415},
	issn = {0893-7648},
	year = {2017},
	eissn = {1559-1182},
	pages = {1482-1499},
	orcid-numbers = {Hendrix, Sven/0000-0003-2344-7369}
}

@article{MTMT:27103669,
	title = {cPKC gamma-mediated down-regulation of UCHL1 alleviates ischaemic neuronal injuries by decreasing autophagy via ERK-mTOR pathway},
	url = {https://m2.mtmt.hu/api/publication/27103669},
	author = {Zhang, Dan and Han, Song and Wang, Shizun and Luo, Yanlin and Zhao, Li and Li, Junfa},
	doi = {10.1111/jcmm.13275},
	journal-iso = {J CELL MOL MED},
	journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
	volume = {21},
	unique-id = {27103669},
	issn = {1582-1838},
	year = {2017},
	eissn = {1582-4934},
	pages = {3641-3657},
	orcid-numbers = {Li, Junfa/0000-0002-1930-9724}
}

@article{MTMT:27103671,
	title = {Comparison of plasma copeptin and multiple biomarkers for assessing prognosis of patients with aneurysmal subarachnoid hemorrhage},
	url = {https://m2.mtmt.hu/api/publication/27103671},
	author = {Zheng, Yong-Ke and Dong, Xiao-Qiao and Du, Quan and Wang, Hao and Yang, Ding-Bo and Zhu, Qiang and Che, Zhi-Hao and Shen, Yong-Feng and Jiang, Li and Hu, Wei and Wang, Ke-Yi and Yu, Wen-Hua},
	doi = {10.1016/j.cca.2017.10.009},
	journal-iso = {CLIN CHIM ACTA},
	journal = {CLINICA CHIMICA ACTA},
	volume = {475},
	unique-id = {27103671},
	issn = {0009-8981},
	year = {2017},
	eissn = {1873-3492},
	pages = {64-69}
}

@article{MTMT:26412732,
	title = {Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids},
	url = {https://m2.mtmt.hu/api/publication/26412732},
	author = {Adrian, Harel and Marten, Kvist and Salla, Nuutinen and Lasse, Valimaa},
	doi = {10.1523/ENEURO.0294-16.2016},
	journal-iso = {ENEURO},
	journal = {ENEURO},
	volume = {3},
	unique-id = {26412732},
	year = {2016},
	eissn = {2373-2822}
}

@article{MTMT:25327721,
	title = {Serum Glial Fibrillary Acidic Protein Predicts Tissue Glial Fibrillary Acidic Protein Break-Down Products and Therapeutic Efficacy after Penetrating Ballistic-Like Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/25327721},
	author = {Boutte, Angela M and Deng-Bryant, Ying and Johnson, David and Tortella, Frank C and Dave, Jitendra R and Shear, Deborah A and Schmid, Kara E},
	doi = {10.1089/neu.2014.3672},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {33},
	unique-id = {25327721},
	issn = {0897-7151},
	year = {2016},
	eissn = {1557-9042},
	pages = {147-156}
}

@article{MTMT:26239291,
	title = {Functional, structural, and neurotoxicity Biomarkers in integrative assessment of Concussions},
	url = {https://m2.mtmt.hu/api/publication/26239291},
	author = {Dambinova, Svetlana A and Maroon, Joseph C and Sufrinko, Alicia M and Mullins, John David and Alexandrova, Eugenia V and Potapov, Alexander A},
	doi = {10.3389/fneur.2016.00172},
	journal-iso = {FRONT NEUR},
	journal = {FRONTIERS IN NEUROLOGY},
	volume = {7},
	unique-id = {26239291},
	issn = {1664-2295},
	year = {2016},
	eissn = {1664-2295}
}

@{MTMT:26476677,
	title = {Folding dynamics and structural basis of the enzyme mechanism of ubiquitin C-terminal hydroylases},
	url = {https://m2.mtmt.hu/api/publication/26476677},
	author = {Danny, Hsu S-T},
	booktitle = {Understanding enzymes : function, design, engineering, and analysis},
	doi = {10.4032/9789814669337},
	publisher = {Jenny Stanford Publishing},
	unique-id = {26476677},
	year = {2016},
	pages = {167-202}
}

@article{MTMT:25967719,
	title = {Exploratory study of serum ubiquitin carboxyl-terminal esterase L1 and glial fibrillary acidic protein for outcome prognostication after pediatric cardiac arrest},
	url = {https://m2.mtmt.hu/api/publication/25967719},
	author = {Fink, Ericka L and Berger, Rachel P and Clark, Robert S B and Watson, R Scott and Angus, Derek C and Panigrahy, Ashok and Richichi, Rudolph and Callaway, Clifton W and Bell, Michael J and Mondello, Stefania and Hayes, Ronald L and Kochanek, Patrick M},
	doi = {10.1016/j.resuscitation.2016.01.024},
	journal-iso = {RESUSCITATION},
	journal = {RESUSCITATION},
	volume = {101},
	unique-id = {25967719},
	issn = {0300-9572},
	year = {2016},
	eissn = {1873-1570},
	pages = {65-70}
}

@article{MTMT:27641256,
	title = {Management of severe traumatic brain injury (first 24 hours)},
	url = {https://m2.mtmt.hu/api/publication/27641256},
	author = {Geeraerts, Thomas and Velly, Lionel and Abdennour, Lamine and Asehnoune, Karim and Audibert, Gerard and Bouzat, Pierre and Bruder, Nicolas and Carrillon, Romain and Cottenceau, Vincent and Cotton, Francois and Courtil-Teyssedre, Sonia and Dahyot-Fizelier, Claire and Dailler, Frederic and David, Jean-Stephane and Engrand, Nicolas and Fletcher, Dominique and Francony, Gilles and Gergele, Laurent and Ichai, Carole and Javouhey, Etienne and Leblanc, Pierre-Etienne and Lieutaud, Thomas and Meyer, Philippe and Mirek, Sebastien and Orliaguet, Gilles and Proust, Francois and Quintard, Herve and Ract, Catherine and Srairi, Mohamed and Tazarourte, Karim and Vigue, Bernard and Payen, Jean-Francois},
	doi = {10.1016/j.anrea.2016.09.007},
	journal-iso = {ANESTHESIE REANIMATION URGENCES},
	journal = {ANESTHESIE REANIMATION URGENCES},
	volume = {2},
	unique-id = {27641256},
	issn = {2352-5800},
	year = {2016},
	eissn = {2352-5819},
	pages = {431-453}
}

@article{MTMT:26405227,
	title = {Phage display for identification of serum biomarkers of traumatic brain injury},
	url = {https://m2.mtmt.hu/api/publication/26405227},
	author = {Ghoshal, Sarbani and Bondada, Vimala and Saatman, Kathryn E and Guttmann, Rodney P and Geddes, James W},
	doi = {10.1016/j.jneumeth.2016.04.026},
	journal-iso = {J NEUROSCI METH},
	journal = {JOURNAL OF NEUROSCIENCE METHODS},
	volume = {272},
	unique-id = {26405227},
	issn = {0165-0270},
	year = {2016},
	eissn = {1872-678X},
	pages = {33-37}
}

@article{MTMT:25796335,
	title = {Usefulness of biomarkers in the prognosis of severe head injuries},
	url = {https://m2.mtmt.hu/api/publication/25796335},
	author = {Gordillo-Escobar, E and Egea-Guerrero, J J and Rodriguez-Rodriguez, A and Murillo-Cabezas, F},
	doi = {10.1016/j.medin.2015.11.008},
	journal-iso = {MED INTENSIVA},
	journal = {MEDICINA INTENSIVA},
	volume = {40},
	unique-id = {25796335},
	issn = {0210-5691},
	year = {2016},
	eissn = {1578-6749},
	pages = {105-112}
}

@article{MTMT:26050017,
	title = {Blood Biomarkers for Evaluation of Perinatal Encephalopathy},
	url = {https://m2.mtmt.hu/api/publication/26050017},
	author = {Graham, Ernest M and Burd, Irina and Everett, Allen D and Northington, Frances J},
	doi = {10.3389/fphar.2016.00196},
	journal-iso = {FRONT PHARMACOL},
	journal = {FRONTIERS IN PHARMACOLOGY},
	volume = {7},
	unique-id = {26050017},
	year = {2016},
	eissn = {1663-9812}
}

@{MTMT:31406435,
	title = {Role of Systems Biology in Brain Injury Biomarker Discovery: Neuroproteomics Application},
	url = {https://m2.mtmt.hu/api/publication/31406435},
	author = {Jaber, Zaynab and Aouad, Patrick and Al, Medawar Mohamad and Bahmad, Hisham and Abou-Abbass, Hussein and Ghandour, Hiba and Mondello, Stefania and Kobeissy, Firas},
	booktitle = {INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS},
	doi = {10.1007/978-1-4939-3816-2_10},
	unique-id = {31406435},
	abstract = {Years of research in the field of neurotrauma have led to the concept of applying systems biology as a tool for biomarker discovery in traumatic brain injury (TBI). Biomarkers may lead to understanding mechanisms of injury and recovery in TBI and can be potential targets for wound healing, recovery, and increased survival with enhanced quality of life. The literature available on neurotrauma studies from both animal and clinical studies has provided rich insight on the molecular pathways and complex networks of TBI, elucidating the proteomics of this disease for the discovery of biomarkers. With such a plethora of information available, the data from the studies require databases with tools to analyze and infer new patterns and associations. The role of different systems biology tools and their use in biomarker discovery in TBI are discussed in this chapter.},
	keywords = {CEREBROSPINAL-FLUID; Biomarkers; GFAP; MINOR HEAD-INJURY; FIBRILLARY ACIDIC PROTEIN; POSTTRAUMATIC-STRESS-DISORDER; NSE; Neurotrauma; Biochemistry & Molecular Biology; Biochemical Research Methods; Neuron-specific enolase; UCHL1; ALPHA-II-SPECTRIN; C-TERMINAL HYDROLASE-L1; Traumatic brain injury TBI; Systems biology tools; SBDPs; SERUM S100B LEVELS; TRAUMATIC BRAIN},
	year = {2016},
	pages = {157-174},
	orcid-numbers = {Bahmad, Hisham/0000-0003-3799-2595; Mondello, Stefania/0000-0002-8587-3614; Kobeissy, Firas/0000-0002-5008-6944}
}

@article{MTMT:25796336,
	title = {Increased plasma UCH-L1 after aneurysmal subarachnoid hemorrhage is associated with unfavorable neurological outcome},
	url = {https://m2.mtmt.hu/api/publication/25796336},
	author = {Kiiski, Heikki and Tenhunen, Jyrki and Ala-Peijari, Marika and Huhtala, Heini and Hamalainen, Mari and Langsjo, Jaakko and Moilanen, Eeva and Narkilahti, Susanna and Ohman, Juha and Peltola, Jukka},
	doi = {10.1016/j.jns.2015.12.046},
	journal-iso = {J NEUROL SCI},
	journal = {JOURNAL OF THE NEUROLOGICAL SCIENCES},
	volume = {361},
	unique-id = {25796336},
	issn = {0022-510X},
	year = {2016},
	eissn = {1878-5883},
	pages = {144-149}
}

@article{MTMT:25442179,
	title = {Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury},
	url = {https://m2.mtmt.hu/api/publication/25442179},
	author = {Korley, Frederick K and Diaz-Arrastia, Ramon and Wu, Alan H B and Yue, John K and Manley, Geoffrey T and Sair, Haris I and Van, Eyk Jennifer and Everett, Allen D and Okonkwo, David O and Valadka, Alex B and Gordon, Wayne A and Maas, Andrew I R and Mukherjee, Pratik and Yuh, Esther L and Lingsma, Hester F and Puccio, Ava M and Schnyer, David M and TRACK-TBI, Investigators},
	doi = {10.1089/neu.2015.3949},
	journal-iso = {J NEUROTRAUM},
	journal = {JOURNAL OF NEUROTRAUMA},
	volume = {33},
	unique-id = {25442179},
	issn = {0897-7151},
	year = {2016},
	eissn = {1557-9042},
	pages = {215-225}
}